AbCellera Biologics Inc DEF 14A, filed Apr 29, 2026
AbCellera Biologics Inc. (ABCL)
DEF 14A
2026-04-29
For: 2025-12-31
View Original
Added on
June 12, 2026
About this DEF 14A
AbCellera Biologics Inc filed this DEF 14A on April 29, 2026.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant x | Filed by a Party other than the Registrant o | ||||
Check the appropriate box:
| o | Preliminary Proxy Statement | ||||
| o | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | ||||
| x | Definitive Proxy Statement | ||||
| o | Definitive Additional Materials | ||||
| o | Soliciting Material Pursuant to §240.14a-12 | ||||
| (Exact name of registrant as specified in its charter) | ||
| (Name of Person(s) Filing Proxy Statement, if other than the Registrant) | ||
Payment of Filing Fee (Check all boxes that apply):
| x | No fee required. | ||||
| o | Fee paid previously with preliminary materials | ||||
| o | Fee computed in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 | ||||
ABCELLERA BIOLOGICS INC.
150 W 4th Avenue
Vancouver, BC V5Y 1G6
NOTICE OF 2026 ANNUAL MEETING OF SHAREHOLDERS
To be held June 11, 2026
Notice is hereby given that the 2026 Annual Meeting of Shareholders, or Annual Meeting, of AbCellera Biologics Inc. will be held virtually on Thursday, June 11, 2026, at 9:00 a.m. Pacific Time. Shareholders may attend the virtual Annual Meeting by visiting www.proxydocs.com/ABCL. To attend the Annual Meeting, you will need your control number, which is included on your notice and proxy card. The purpose of the Annual Meeting is the following:
1.To elect two class III directors to our Board of Directors, to serve until the 2029 Annual Meeting of Shareholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;
3.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers, or Say-on-Pay;
4.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
The proposal for the election of directors relates solely to the election of class III directors nominated by the Board of Directors.
Only shareholders of record at the close of business on April 15, 2026, will be entitled to vote during the Annual Meeting and any adjournment or postponement thereof. To join the Annual Meeting, you will need your control number, which is included on your notice and proxy card. You will not be able to attend the 2026 Annual Meeting in person.
We are pleased to take advantage of Securities and Exchange Commission rules that allow companies to furnish their proxy materials over the Internet. We are mailing to our shareholders a Notice of Internet Availability of Proxy Materials (Notice) instead of a paper copy of our proxy materials and our 2025 Annual Report to Shareholders (2025 Annual Report). The Notice contains instructions on how to access those documents and to cast your vote online. The Notice also contains instructions for requesting a paper copy of our proxy materials and our 2025 Annual Report. This process allows us to provide our shareholders with the necessary information more promptly, reduce environmental impact, and lower the costs of printing and distributing our proxy materials.
Your vote is important. Whether or not you can attend the virtual Annual Meeting, it is important that your shares be represented. To ensure your vote is recorded promptly, please cast it as soon as possible, even if you plan to attend the virtual Annual Meeting. You may vote by submitting your proxy via the Internet, by telephone, or by mail (if you received paper copies of the proxy materials) by following the instructions on the proxy card or voting instruction card. Voting over the Internet or by telephone, a written proxy, or a voting instruction card will ensure your representation at the virtual Annual Meeting regardless of whether you attend.
| By direction of the Board of Directors, | |||||
| /s/ Tryn T. Stimart | |||||
Tryn T. Stimart Chief Legal Officer, Chief Compliance Officer, Corporate Secretary, and Privacy Officer | |||||
Vancouver, BC
April 29, 2026
Table of Contents
| Page | |||||
i
ABCELLERA BIOLOGICS INC.
150 W 4th Avenue
Vancouver, BC V5Y 1G6
PROXY STATEMENT
FOR THE 2026 ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD June 11, 2026
This proxy statement contains information about the 2026 Annual Meeting of Shareholders, or the Annual Meeting, of AbCellera Biologics Inc., which will be held on Thursday, June 11, 2026, at 9:00 a.m. Pacific Time. The 2026 Annual Meeting will be a virtual shareholders’ meeting held at www.proxydocs.com/ABCL. Our Board of Directors is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, the terms “AbCellera,” “Company,” “we,” “us,” and “our” refer to AbCellera Biologics Inc. The mailing address of our principal executive offices is 150 W 4th Avenue, Vancouver, BC V5Y 1G6.
All properly submitted proxies will be voted in accordance with the instructions contained therein. If no instructions are specified, the proxies will be voted in accordance with the recommendation of our Board of Directors on each of the matters set forth in the accompanying Notice of Meeting. You may revoke your proxy at any time before it is exercised at the meeting by giving our proxy tabulator written notice to that effect. Such written notice should be delivered by mail to Proxy Tabulator for AbCellera Biologics Inc., c/o Odyssey Transfer & Trust Company, 2155 Woodlane Dr, Suite 100, Woodbury, MN 55125.
We made this proxy statement and our Annual Report to Shareholders for the fiscal year ended December 31, 2025, available to shareholders on or about April 29, 2026.
Important Notice Regarding the Availability of Proxy Materials for
the Annual Meeting of Shareholders to be Held on June 11, 2026:
This proxy statement and our 2025 Annual Report to Shareholders are
available for viewing, printing and downloading at www.proxydocs.com/ABCL.
A copy of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, except for exhibits, will be furnished without charge to any shareholder upon written request to AbCellera Biologics Inc., 150 W 4th Avenue, Vancouver, BC V5Y 1G6, Attention: Corporate Secretary. This proxy statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 are also available on the SEC’s website at www.sec.gov and on our website at www.abcellera.com.
1
ABCELLERA BIOLOGICS INC.
PROXY STATEMENT
FOR THE 2026 ANNUAL MEETING OF SHAREHOLDERS
GENERAL INFORMATION
When is this proxy statement and the accompanying materials scheduled to be sent to shareholders?
We have elected to provide our proxy materials to shareholders via the Internet. Accordingly, on or about April 29, 2026, we will begin mailing a Notice of Internet Availability of Proxy Materials, or Notice.
Our proxy materials will be mailed or made available to shareholders on the Internet on or about the same date and includes:
1.Notice of 2026 Annual Meeting of Shareholders;
2.This proxy statement and the accompanying proxy card or, for shares held in street name (i.e., held for your account by a broker or other nominee);
3.A voting instruction form; and
4.The 2025 Annual Report to Shareholders, or 2025 Annual Report.
Why did I receive a Notice of Internet Availability of Proxy Materials instead of a full set of proxy materials?
Pursuant to SEC rules, we are providing most shareholders with access to our proxy materials over the Internet rather than printing and mailing them. We believe following this process will expedite the receipt of such materials and will help lower our costs and reduce the environmental impact of our Annual Meeting materials. Therefore, the Notice was mailed to holders of record and beneficial owners of our common shares starting on or about April 29, 2026. The Notice provides instructions as to how shareholders may access and review our proxy materials, including the Notice of 2026 Annual Meeting of Shareholders, this proxy statement, the proxy card and our 2025 Annual Report, on the website referred to in the Notice or, alternatively, how to request that a copy of the proxy materials, including a proxy card, be sent to them by mail. The Notice also provides voting instructions. In addition, shareholders of record may request to receive the proxy materials in printed form by mail or electronically by e-mail on an ongoing basis for future shareholders’ meetings. Please note that, while our proxy materials are available at the website referenced in the Notice, and our Notice of 2026 Annual Meeting of Shareholders, this proxy statement and our 2025 Annual Report are available on our website. No other information contained on either website is incorporated by reference in or considered to be a part of this proxy statement.
Who is soliciting my vote?
Our Board of Directors is soliciting your vote for the Annual Meeting.
When is the record date for the Annual Meeting?
The record date for the determination of shareholders entitled to vote at the Annual Meeting is the close of business on April 15, 2026.
How many votes can be cast by all shareholders?
There were 305,264,947 common shares, no par value per share, outstanding on April 15, 2026, all of which are entitled to vote with respect to all matters to be acted upon at the Annual Meeting. Each shareholder of record is entitled to one (1) vote for each share of our common shares held by such shareholder. We had no undesignated preferred shares outstanding as of April 15, 2026.
Where will the Annual Meeting be held this year?
The 2026 Annual Meeting will be a virtual shareholders’ meeting held at www.proxydocs.com/ABCL.
We are committed to ensuring that shareholders will be afforded the same rights and opportunities to participate as they would at an in-person meeting. To attend the virtual Annual Meeting and vote your shares, shareholders of record as of April 15, 2026, can access www.proxydocs.com/ABCL. To join the Annual Meeting, you will need your control number
2
which is included on your notice and proxy card. If you do not have a control number, please contact your broker, bank, or other nominee as soon as possible so you can obtain a control number and gain access to the meeting.
We will not charge you for access to the virtual Annual Meeting, though your internet service provider may charge a fee for network access. Even if you plan to attend the Annual Meeting virtually, we recommend that you also vote by proxy as described herein so that your vote will be counted if you decide not to attend the Annual Meeting.
How do I vote?
If you are a shareholder of record, there are several ways for you to vote your shares.
•Online during the Annual Meeting. You may vote during the virtual Annual Meeting by following the instructions available at www.proxydocs.com/ABCL. If you hold your shares through a bank or broker and wish to vote at the virtual Annual Meeting, you must obtain a valid proxy from the firm that holds your shares. To join the Annual Meeting, you will need your control number, which is included on your notice and proxy card. If you do not have a control number, please contact your broker, bank, or other nominee as soon as possible so you can obtain a control number and gain access to the meeting.
•By Internet or Telephone prior to the Annual Meeting. You can vote by proxy over the Internet or by telephone by following the instructions provided in the Notice. To be counted, proxies submitted by Internet or by telephone must be received by the cutoff time of 11:59 a.m. Eastern Time on June 11, 2026.
•By Mail prior to the Annual Meeting. If you requested printed copies of the proxy materials by mail, you can vote by mailing your proxy as described in the proxy materials. Proxies submitted by mail must be received before the start of the Annual Meeting.
If you complete and submit your proxy before the Annual Meeting, the persons named as proxies will vote the shares represented by your proxy in accordance with your instructions. If you submit a proxy without giving voting instructions, your shares will be voted in the manner recommended by the Board of Directors on all matters presented in this proxy statement, and as the persons named as proxies may determine in their discretion with respect to any other matters properly presented at the Annual Meeting. You may also authorize another person or persons to act for you as proxy in writing, signed by you or your authorized representative, specifying the details of those proxies’ authority. The original writing must be given to each of the named proxies, although it may be sent to them by electronic transmission if, from that transmission, it can be determined that the transmission was authorized by you.
If any other matters are properly presented for consideration at the Annual Meeting, including, among other things, consideration of a motion to adjourn the Annual Meeting to another time or place (including, without limitation, for the purpose of soliciting additional proxies), the persons named in your proxy and acting thereunder will have discretion to vote on those matters in accordance with their best judgment. We do not currently anticipate that any other matters will be raised at the Annual Meeting.
How do I revoke my proxy?
You may revoke your proxy by (1) following the instructions on the Notice and entering a new vote by mail that we receive before the start of the Annual Meeting or over the Internet by the cutoff time of 11:59 a.m. Eastern Time on June 11, 2026, (2) attending and voting at the virtual Annual Meeting (although attendance at the virtual Annual Meeting will not in and of itself revoke a proxy), or (3) by filing an instrument in writing revoking the proxy or another duly executed proxy bearing a later date with our Corporate Secretary. Any written notice of revocation or subsequent proxy card must be received by our proxy tabulator prior to the taking of the vote at the Annual Meeting. Such written notice of revocation or subsequent proxy card should be delivered by mail to Proxy Tabulator for AbCellera Biologics Inc., c/o Odyssey Transfer & Trust Company, 2155 Woodlane Dr, Suite 100, Woodbury, MN 55125.
If a broker, bank, or other nominee holds your shares, you must contact such broker, bank, or nominee to find out how to change your vote.
How is a quorum reached?
Our articles provide that two (2) persons who are, or who represent by proxy, shareholders who, in the aggregate, hold at least a majority of the issued shares entitled to be voted at the meeting, will constitute a quorum for the transaction of business at the Annual Meeting.
3
Shares that are voted “abstain” or “withheld” and broker “non-votes” are counted as present for purposes of determining whether a quorum is present at the Annual Meeting. If a quorum is not present, the meeting may be adjourned until a quorum is obtained.
How is the vote counted?
Under our articles and the British Columbia Business Corporations Act, or BCBCA, proposals are generally decided by a majority of the votes cast by the shareholders who voted in respect of that resolution, except where a larger or different vote is required by law or by our articles. Because abstentions are not counted as votes, they are not counted as votes in favor of any proposal.
A broker “non-vote” occurs when a nominee holding shares for a beneficial owner does not vote on a particular proposal because the nominee lacks discretionary voting power with respect to that item and has not received instructions from the beneficial owner. Because broker “non-votes” are not votes cast by shareholders, they are not included in the tabulation of the voting results on any such proposal and, therefore, do not have an impact on such proposals.
If your shares are held in “street name” by a brokerage firm, your brokerage firm is required to vote your shares according to your instructions. If you do not give instructions to your brokerage firm, the brokerage firm will still be able to vote your shares with respect to certain “discretionary” items, but they will not be allowed to vote your shares with respect to “non-discretionary” items. Each of Proposals No. 1 and 3 is a “non-discretionary” item. If you do not instruct your broker how to vote with respect to these proposals, your broker may not vote for such proposals, and those votes will be counted as broker “non-votes.” Proposal No. 2 is a discretionary item, and your brokerage firm will be able to vote on this proposal even if it does not receive instructions from you.
To be elected, each director nominated under Proposal No. 1 must receive a “for” vote from a majority of the votes cast by shareholders voting on such proposal. We have adopted a “majority voting policy” to the effect that a nominee for election as a director who does not receive a majority of “for” votes compared to the total number of votes cast with respect to the election of directors by shareholders shall offer to tender his or her resignation to the Board of Directors promptly following the meeting of shareholders at which the vote took place. The nominating and corporate governance committee will consider such offer and make a recommendation to our Board of Directors whether to accept such resignation. Our Board of Directors will promptly accept the resignation unless it determines, in consultation with the nominating and corporate governance committee, that there are exceptional circumstances that warrant delaying its acceptance or justify rejecting it. Our Board of Directors will make its decision and disclose it in a Current Report on Form 8-K within ninety (90) days following the meeting of shareholders. A director who tenders a resignation pursuant to our majority voting policy will not participate in any meeting of our Board of Directors or the nominating and corporate governance committee at which the resignation is considered. Our majority voting policy does not apply for contested meetings at which the number of directors nominated for election is greater than the number of seats available on the Board of Directors.
For Proposal No. 2 to pass, it must receive a “for” vote from a majority of the votes cast by shareholders voting in respect of the proposal.
For Proposal No. 3 to pass, it must receive a “for” vote from a majority of the votes cast by shareholders voting in respect of the proposal.
Who pays the cost for soliciting proxies?
We are making this solicitation and will pay the entire cost of preparing and distributing the Notice and our proxy materials and soliciting votes. If you choose to access the proxy materials or vote over the Internet, you are responsible for any Internet access charges that you may incur. Our officers and employees may, without additional compensation, solicit proxies through further mailings, personal conversations, facsimile transmissions, e-mails, or otherwise. We have retained Odyssey Transfer & Trust Company to assist us in the distribution of proxy materials. Proxy solicitation expenses we will pay include preparation, mailing, returning, and tabulation of the proxies.
How may shareholders submit matters for consideration at an Annual Meeting?
With respect to shareholder proposals, we are subject to the provisions of the BCBCA, which sets out the requirements for a valid proposal and provides for the rights and obligations of our company and the submitter upon a valid proposal being made. Proposals submitted under the applicable provisions of the BCBCA that a shareholder intends to present at the 2026 Annual Meeting and wishes to be considered for inclusion in our proxy statement and form of proxy relating to the 2026
4
Annual Meeting must be received at least three (3) months before the anniversary of the 2025 Annual Meeting. Such proposals must also comply with all applicable provisions of the BCBCA and the regulations thereunder.
In addition, any shareholder proposal intended to be included in the proxy statement for the next Annual Meeting of our shareholders in 2027 must also satisfy the requirements of SEC Rule 14a-8 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and be received not later than December 31, 2026. If the date of the Annual Meeting is moved by more than thirty (30) days from the date contemplated at the time of the previous year’s proxy statement, then notice must be received within a reasonable time before we begin to print and send proxy materials. If that happens, we will publicly announce the proposal submission deadline in a press release or in a document filed with the SEC.
Further, to comply with the universal proxy rules, shareholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than April 13, 2027.
How can I know the voting results?
We plan to announce preliminary voting results at the Annual Meeting and will publish final results in a Current Report on Form 8-K to be filed with the SEC within four (4) business days following the Annual Meeting.
5
PROPOSAL NO. 1 – ELECTION OF CLASS III DIRECTORS
Our Board of Directors currently consists of five (5) members. In accordance with the terms of our articles, our Board of Directors is divided into three (3) classes (class I, class II and class III) with members of each class serving staggered three-year terms. The members of the classes are divided as follows:
•the class III directors are John S. Montalbano, CFA, and Stephen R. Quake, D.Phil., and their terms will expire at the Annual Meeting;
•the class I director is Véronique Lecault, Ph.D. and her term will expire at the Annual Meeting of Shareholders to be held in 2027;
•the class II directors are Carl L. G. Hansen, Ph.D. and Michael Hayden, MBCHB (M.D.), Ph.D., and their terms will expire at the Annual Meeting of Shareholders to be held in 2028.
Following the initial term of office described above, directors will be elected to hold office for a three-year term expiring on the third annual general meeting following their election. At every annual general meeting and in every unanimous shareholder resolution in lieu thereof, all of the directors whose terms expire shall cease to hold office immediately before the election or appointment of directors, and they are eligible for re-election or re-appointment. The shareholders entitled to vote at the annual general meeting for the election of directors may elect, or in a unanimous resolution appoint, the number of directors required to fill any vacancies created, which vacancies have not already been filled as otherwise permitted in the articles. The directors will hold office for the applicable terms contemplated in the staggered board provisions. Upon resignation of a director, the remaining directors may fill the casual vacancy resulting from such resignation for the remainder of the unexpired term.
On November 6, 2025, Andrew Lo, Ph.D., then a member of the Board of Directors, the Chairman of the Nominating and Corporate Governance Committee, and a member of the Audit Committee, notified the Company of his intention to retire from the Company’s Board of Directors and all committees. Dr. Lo did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices. Effective November 6, 2025, the Company appointed Stephen R. Quake, D.Phil., as a member of the Company’s Board of Directors and was appointed to the Audit Committee and Chairman of the Nominating and Corporate Governance Committee.
Under the BCBCA and our articles, a director may be removed with or without cause by a special resolution passed by a special majority (being two-thirds) of the votes cast by shareholders present in person or by proxy at a duly convened meeting and who are entitled to vote. To the extent directors are elected or appointed to fill casual vacancies or vacancies arising from the removal of directors, in both instances whether by shareholders or directors, the directors shall hold office until the remainder of the unexpired portion of the term of the departed director that was replaced. Any casual vacancy occurring on the Board of Directors may be filled by the directors, subject to our articles. In addition, if our company has no directors or fewer directors in office than the number set pursuant to our articles as the quorum of directors, then the shareholders may elect or appoint directors to fill any vacancies on the Board of Directors, subject to our articles.
Our Board of Directors has nominated each of John S. Montalbano, CFA, and Stephen R. Quake, D.Phil., for election as the class III directors at the Annual Meeting. The nominees are presently directors and have indicated a willingness to continue to serve as directors, if elected. If the nominees become unable or unwilling to serve, however, the proxies may be voted for a substitute nominee selected by our Board of Directors.
Our priority in the selection of board members is the identification of members who will further the interests of our shareholders through consideration of several facts and circumstances, including among other things, the skills of the prospective director candidate, his or her depth and breadth of business experience or other background characteristics, his or her independence, and the needs of the Board of Directors.
Nominees for Election as Class III Directors
The following table and narrative information identifies our nominees for class III directors, sets forth their principal occupation and business experience during the last five years, indicates their start date as a director, and states their age as of April 1, 2026.
| Name | Positions and Offices Held | Director Since | Age | |||||||||||||||||||||||
| John S. Montalbano, CFA | Director | 2020 | 61 | |||||||||||||||||||||||
Stephen R. Quake, D.Phil. | Director | 2025 | 56 | |||||||||||||||||||||||
6
John S. Montalbano, CFA. Mr. Montalbano has served as a member of our Board of Directors since November 2020 and is the Chair of our Audit Committee, a member of our Compensation Committee, and a member of our Nominating and Corporate Governance Committee. Mr. Montalbano served as a member of the Board of Directors of Aritzia Inc., a public fashion company, from July 2019 to February 2025, has served as a member of the Board of Directors and Audit Committee Chair for the Canada Pension Plan Investment Board, since February 2017, and served as a member of the Board of Directors of Manulife Financial Corporation since February 2025. Prior to his retirement, Mr. Montalbano served as the Chief Executive Officer of RBC Global Asset Management from 2008 to 2015, and as the President of Phillips, Hager & North Investment Management Ltd., a private wealth management firm, from 2005 to 2008. Mr. Montalbano also served as Vice Chair of RBC Wealth Management from April 2015 to December 2016. Mr. Montalbano holds a B.Comm. in Finance from the University of British Columbia. We believe Mr. Montalbano is qualified to serve on our Board of Directors due to his leadership, experience as an entrepreneur, and financial expertise.
Stephen R. Quake, D.Phil. Dr. Quake has served as a member of our Board of Directors since November 2025. Dr. Quake has been a Professor at Stanford University since 2005 and is currently the Lee Otterson Professor of Bioengineering and Professor of Applied Physics. Dr. Quake is a prolific inventor in the fields of DNA sequencing and microfluidic automation, and his innovations have led to the development of non-invasive prenatal tests and other diagnostic tools. He currently serves on the Board of Directors of Tachyon Therapeutics, IgGenix Inc., Superfluid DX, ClearNote Health, Kanvas, and Mirvie. He previously served on the Board of Directors of CM Life Sciences II/Somalogic from 2020 to 2022. Dr. Quake holds a B.S. in Physics and an M.S. in Mathematics from Stanford University, and a D.Phil. in Theoretical Physics from the University of Oxford. We believe Dr. Quake is qualified to serve on our Board of Directors due to his extensive academic background in bioengineering and applied physics, his significant experience as an inventor and entrepreneur in the life sciences sector, and his leadership experience in major research organizations.
Vote Required
To be elected, each director nominated must receive a “for” vote from a majority of the votes cast by shareholders who voted in respect of this proposal. Abstentions and broker non-votes will have no effect on this proposal. We have adopted a “majority voting policy” to the effect that a nominee for election as a director who does not receive a majority of “for” votes compared to the total number of votes cast with respect to the election of directors by shareholders shall offer to tender his or her resignation to the Board of Directors promptly following the meeting of shareholders at which the vote took place. The nominating and corporate governance committee will consider such offer and make a recommendation to our Board of Directors whether to accept such resignation. Our Board of Directors will promptly accept the resignation unless it determines, in consultation with the nominating and corporate governance committee, that there are exceptional circumstances that should delay the acceptance of the resignation or justify rejecting it. Our Board of Directors will make its decision and disclose it in a Current Report on Form 8-K within ninety (90) days following the meeting of shareholders. A director who tenders a resignation pursuant to our majority voting policy will not participate in any meeting of our Board of Directors or the nominating and corporate governance committee at which the resignation is considered. Our majority voting policy does not apply for contested meetings at which the number of directors nominated for election is greater than the number of seats available on the Board of Directors.
THE BOARD OF DIRECTORS RECOMMENDS VOTING “FOR” THE ELECTION OF JOHN S. MONTALBANO, CFA, AND STEPHEN R. QUAKE, D.PHIL., AS THE CLASS III DIRECTORS, TO SERVE FOR A THREE-YEAR TERM ENDING AT THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD IN 2029.
Directors Continuing in Office
The following table and narrative information identifies our directors continuing in office and sets forth their principal occupation and business experience during the last five years and their ages as of April 1, 2026.
| Name | Positions and Offices Held | Director Since | Class and Year in Which Term Will Expire | Age | ||||||||||||||||||||||
Véronique Lecault, Ph.D. | Chief Technology Officer and Director1 | 2018 | Class I—2027 | 41 | ||||||||||||||||||||||
| Carl L.G. Hansen, Ph.D. | Chief Executive Officer, President and Director (Chairman of the Board) | 2012 | Class II—2028 | 51 | ||||||||||||||||||||||
| Michael Hayden, MBCHB (M.D.), Ph.D. | Lead Director | 2019 | Class II—2028 | 74 | ||||||||||||||||||||||
7
1Effective February 18, 2025, Dr. Véronique Lecault transitioned from Chief Operating Officer (COO) to Chief Technology Officer (CTO).
Class I Director (Term Expires at 2027 Annual Meeting)
Véronique Lecault, Ph.D. Dr. Lecault is a co-founder and has served in various positions with us since November 2012. Dr Lecault was our Chief Operating Officer from January 2019 to February 2025, and has served as our Chief Technology Officer since February 2025, and a member of our Board of Directors since August 2018. Dr. Lecault received her Ph.D. in Chemical and Biological Engineering from the University of British Columbia where she co-invented the high-throughput microfluidic platform that is now part of our core technology. Dr. Lecault holds a B.A.Sc. in Chemical Engineering/Honours B.Sc. Biochemistry (Biotechnology) dual degree from the University of Ottawa. We believe Dr. Lecault is qualified to serve on our Board of Directors because of the perspective and experience she brings as an officer and as one of our co-founders.
Class II Directors (Term Expires at 2028 Annual Meeting)
Carl L. G. Hansen, Ph.D. Dr. Hansen is our co-founder and has served as our Chief Executive Officer, President and as the Chairman of our Board of Directors since our inception in November 2012. Dr. Hansen co-founded Precision NanoSystems Inc., a Vancouver-based private company developing next-generation delivery technology for genetic medicines founded in 2010, where Dr. Hansen also served as a member of the Board of Directors from January 2011 to September 2015. Until August 2019, Dr. Hansen was a professor at the University of British Columbia, where he coauthored over 65 manuscripts in the fields of microfluidics, immunology, genomics and nanotechnology. Dr. Hansen also was a co-founder and served as a member of the Board of Directors of Resolution Diagnostics, a private genomics technology company, from May 2015 to April 2016. Prior to that, he served on the science advisory board of Fluidigm Corporation, a public company providing biotechnology tools, from January 2008 to January 2012. Dr. Hansen holds a Ph.D. in Applied Physics with a focus on Biotechnology from the California Institute of Technology, and a B.A.Sc. in Engineering Physics and Honors Mathematics from the University of British Columbia. We believe Dr. Hansen is qualified to serve on our Board of Directors because of the perspective and experience he brings as a co-founder and our Chief Executive Officer.
Michael Hayden, MBCHB (M.D.), Ph.D. Dr. Hayden has served as a member of our Board of Directors since September 2019. Dr. Hayden is the Lead director of the Board of Directors and serves as the Chair of our Compensation Committee, is a member of our Nominating and Corporate Governance Committee, and a member of our Audit Committee. Dr. Hayden has been the Chief Executive Officer of Prilenia Therapeutics B.V., a clinical stage biotechnology company since September 2018. From September 2012 to December 2017, Dr. Hayden served as Chief Science Officer and President of Global Research and Development at Teva Pharmaceutical Industries Ltd., a public pharmaceutical company. Dr. Hayden has founded a number of biotechnology companies, including Aspreva Pharmaceuticals Limited, a private pharmaceutical company; Neurovir Therapeutics, Inc., a private biopharmaceutical company; Xenon Pharmaceuticals Inc., a public clinical-stage biopharmaceutical company; and 89bio, Inc., a public clinical-stage biopharma company. Dr. Hayden has served as a member of the Board of Directors for each of Ionis Pharmaceuticals Inc., a public biotechnology company, since September 2018; 89bio since April 2018, and Xenon Pharmaceuticals Inc. from November 1996 to June 2022. From September 2018 to June 2020, Dr. Hayden also served as the executive chairman of the Board of Directors of Prilenia. Dr. Hayden is also a Killam Professor of Medical Genetics at the University of British Columbia, a Founder and Senior Scientist at the Centre for Molecular Medicine and Therapeutics, and a Canada Research Chair in Human Genetics and Molecular Medicine. Dr. Hayden holds an M.B., Ch.B. (M.D.) and a Ph.D. degree in Genetics from the University of Cape Town. He is board certified by the American Societies of Internal Medicine and Medical Genetics. He is also certified by the Royal College of Physicians of Canada (Internal Medicine). We believe Dr. Hayden is qualified to serve on our Board of Directors because of his academic background, as well as his extensive experience as a director and executive officer of both publicly and privately held biotechnology and biopharmaceutical companies.
The proxies will be voted in favor of the above nominees unless a contrary specification is made in the proxy. The nominees have consented to serve as our directors if elected. However, if the nominees are unable to serve or for good cause will not serve as a director, the proxies will be voted for the election of such substitute nominee as our Board of Directors may designate.
There are no family relationships between or among any of our directors or executive officers. The principal occupation and employment during the past five years of each of our directors was carried on, in each case except as specifically identified above, with a corporation or organization that is not a parent, subsidiary or other affiliate of us. There is no arrangement or understanding between any of our directors and any other person or persons pursuant to which he or she is to be selected as a director.
8
There are no material legal proceedings to which any of our directors is a party adverse to us or any of our subsidiaries or in which any such person has a material interest adverse to us or our subsidiaries.
Executive Officers Who Are Not Directors
The following table identifies our executive officers who are not directors and sets forth their current positions at the Company and their ages as of April 1, 2026.
| Name | Position Held | Officer Since | Age | |||||||||||||||||
| Andrew Booth | Chief Financial Officer | 2019 | 52 | |||||||||||||||||
| Tryn Stimart | Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer | 2019 | 56 | |||||||||||||||||
Andrew Booth. Mr. Booth has served as our Chief Financial Officer since August 2019, and he previously served as a member of our Board of Directors from June 2016 to August 2019. From February 2017 to July 2019, Mr. Booth also served as the Chief Commercial Officer of STEMCELL Technologies Inc., a Vancouver-based private biotechnology company, and as the Chief Financial Officer of STEMCELL Technologies from March 2013 to January 2017, and as the VP, Instrumentation from January 2010 to February 2013. Prior to STEMCELL, Mr. Booth was at GE Healthcare based in London, UK leading M&A activities for EMEA and GE Lifesciences. Mr. Booth was at GE from 2004 to 2009. Mr. Booth has also previously served as a member of the Board of Directors of various private companies in the life sciences sector. Mr. Booth holds an MBA from INSEAD and a B.A.Sc. in Engineering Physics from the University of British Columbia.
Tryn Stimart. Mr. Stimart has served as our Chief Legal Officer and Corporate Secretary since August 2019, our Chief Compliance Officer since December 2020, and our Privacy Officer since 2023. Prior to joining AbCellera, Mr. Stimart was a partner at Gibbons P.C., a law firm, from October 2016 to August 2019. From May 2013 to September 2016, Mr. Stimart was a partner at Womble Bond, LLP, a law firm. Mr. Stimart holds a J.D. from the American University Washington College of Law, an M.Sc. in Chemistry from Old Dominion University, and B.Scs. degrees in Biochemistry and Genetics & Cell Biology from the University of Minnesota (twin cities).
9
PROPOSAL NO. 2 – RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP
AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE
FISCAL YEAR ENDING DECEMBER 31, 2026
Our shareholders are being asked to ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.
The Audit Committee is solely responsible for selecting our independent registered public accounting firm for the fiscal year ending December 31, 2026. Shareholder approval is not required to appoint Ernst & Young LLP as our independent registered public accounting firm; however, the Board of Directors believes that submitting the appointment of Ernst & Young LLP to the shareholders for ratification is good corporate governance. If the shareholders do not ratify this appointment, the Audit Committee will reconsider whether to retain Ernst & Young LLP. If the selection of Ernst & Young LLP is ratified, the Audit Committee, at its discretion, may direct the appointment of a different independent registered public accounting firm at any time it decides that such a change would be in the best interest of our company and its shareholders.
A representative of Ernst & Young LLP is expected to be present at the virtual Annual Meeting and will have an opportunity to make a statement if he or she desires to do so and to respond to appropriate questions from our shareholders.
Changes in Independent Registered Public Accounting Firm
As previously disclosed in our Current Report on Form 8-K filed on November 28, 2025, the Audit Committee approved the engagement of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026, and the dismissal of KPMG LLP upon the completion of the audit of our consolidated financial statements for the fiscal year ended December 31, 2025. KPMG LLP has served as our independent registered public accounting firm since 2017. The dismissal was not related to any disagreements with KPMG LLP on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure. During the fiscal years ended December 31, 2024 and December 31, 2025, and the subsequent interim period through the filing date of our Annual Report on Form 10-K on February 24, 2026, there were no i) disagreements as defined in Item 304(a)(1)(iv) of Regulation S-K between the Company and KPMG LLP on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, and ii) no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K.
The following table sets forth all fees paid or accrued by us for professional audit services and other services rendered by KPMG LLP during the years ended December 31, 2024, and December 31, 2025.
| 2024 | 2025 | |||||||||||||
Audit fees(1) | $ | 775,200 | $ | 997,660 | ||||||||||
Audit-related fees(2) | – | – | ||||||||||||
Tax fees(3) | 181,774 | 6,624 | ||||||||||||
| All other fees | – | – | ||||||||||||
Total fees(4) | $ | 956,974 | $ | 1,004,284 | ||||||||||
__________________________
(1)Audit fees consist of fees for professional services provided by KPMG LLP for the audits of our annual consolidated financial statements and effectiveness of internal control over financial reporting, the review of interim consolidated financial statements, consultations on accounting matters directly related to the audit, and comfort letters, consents and assistance with and review of documents filed with the SEC.
(2)Fees not included in audit fees that are billed by the auditor for assurance and related services that are reasonably related to the performance of the financial statements. There were no such fees incurred in 2024 or 2025.
(3)Tax Fees consist of fees for professional services in connection with tax compliance, tax planning, and tax advice, including the review and preparation of our federal, state and foreign income tax returns and requests for rulings or technical advice from tax authorities.
(4)Fees paid in Canadian dollars have been converted to U.S. dollars at the average exchange rate of CAD $1.37:USD $1.00 for the year ended December 31, 2024, and CAD $1.40:USD $1.00 for the year ended December 31, 2025, respectively, based on Bank of Canada average exchange rates.
Audit Committee Pre-Approval Policy and Procedures
Our Audit Committee has adopted policies and procedures relating to the approval of all audit and non-audit services that are to be performed by our independent registered public accounting firm. This policy provides that we will not engage our independent registered public accounting firm to render audit or non-audit services unless the service is specifically
10
approved in advance by our Audit Committee or the engagement is entered into pursuant to the pre-approval procedure described below.
From time to time, our Audit Committee may pre-approve specified types of services that are expected to be provided to us by our independent registered public accounting firm during the next 12 months. Any such pre-approval details the particular service or type of services to be provided and is also generally subject to a maximum dollar amount.
During our 2024 and 2025 fiscal years, no services were provided to us by KPMG LLP other than in accordance with the pre-approval policies and procedures described above.
Vote Required
This proposal must receive the affirmative vote of the majority of shares properly cast on the proposal to ratify the appointment of Ernst & Young LLP. Abstentions will have no effect on this proposal. If your shares are held in “street name” by a broker, bank or other nominee, your broker, bank or other nominee has authority to vote your unvoted shares held by the firm on this proposal. If your broker, bank or other nominee does not exercise this authority, such broker non-votes will have no effect on the results of this proposal.
THE BOARD OF DIRECTORS RECOMMENDS VOTING “FOR” PROPOSAL NO. 2 TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
11
PROPOSAL NO. 3 – NON-BINDING ADVISORY VOTE ON NAMED EXECUTIVE COMPENSATION
Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Section 14A(a)(1) of the Exchange Act, we are required to solicit our shareholders at least once every three (3) years, to vote, with an opportunity to cast a non-binding advisory vote on the compensation of our named executive officers, or a “Say-On-Pay Vote”, as disclosed in this proxy statement. At our 2025 Annual Meeting of Shareholders, our shareholders voted on, among other matters, a proposal regarding the frequency of holding a non-binding advisory vote on the compensation of our named executive officers. A majority of the votes cast on the frequency proposal were cast in favor of holding a non-binding, advisory vote on the compensation of our named executive officers every year, which was consistent with the recommendation of the Board. The Board considered the voting results with respect to the frequency proposal as well as other factors, and currently intends for the Company to hold a non-binding advisory vote on the compensation of our named executive officers every year until the next required non-binding advisory vote on the frequency of holding the non-binding, advisory vote on the compensation of our named executive officers, which will occur not later than the 2028 Annual Meeting of Shareholders. As a result, our Board of Directors is providing the shareholders with an opportunity to partake, on a non-binding advisory basis, in a Say-On-Pay Vote.
As described below under “Executive Compensation – Compensation Discussion & Analysis,” we have developed a compensation program that is designed to attract and retain key executives responsible for our success and motivate management to enhance long-term shareholder value. The executive compensation program is designed to reward both short-term and long-term performance and to align the financial interests of our executive officers with the interests of our shareholders. We believe our executive compensation program strikes an appropriate balance between the implementation of responsible, measured compensation practices, and the effective provision of incentives for our named executive officers to exert their best efforts for our success.
We are asking for shareholder approval, on a non-binding advisory basis, of the compensation of our named executive officers as disclosed in this Proxy Statement, which includes the disclosures in the “Executive Compensation” and “Compensation Discussion & Analysis” sections, the compensation tables, and the narrative discussion following the compensation tables in this Proxy Statement. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the policies and practices described in this Proxy Statement. For the reasons discussed above, our Board of Directors unanimously recommends that our shareholders vote in favor of the following resolution:
“RESOLVED, that the Company’s shareholders hereby approve, on a non-binding advisory basis, the compensation of the named executive officers, as disclosed in the Company’s Proxy Statement for the 2026 Annual Meeting of Shareholders pursuant to the compensation disclosure rules of the SEC, including the Compensation Discussion and Analysis, 2025 Summary Compensation Table, and the other compensation-related tables and the narratives that accompany such tables.”
As this vote is advisory, it will not be binding upon our Board of Directors or the Compensation Committee, and neither our Board of Directors nor the Compensation Committee will be required to take any action as a result of the outcome of this vote. However, the Board of Directors and the Compensation Committee value the opinion of our shareholders, and the Compensation Committee will carefully consider the outcome of this vote when evaluating our executive compensation policies and practices and making future compensation decisions.
Vote Required
This proposal must receive the affirmative vote of the majority of shares properly cast on the proposal to approve, on a non-binding advisory basis, the compensation of our named executive officers. Abstentions and broker non-votes will have no effect on this proposal.
THE BOARD OF DIRECTORS RECOMMENDS VOTING “FOR” THE NON-BINDING ADVISORY RESOLUTION IN PROPOSAL NO. 3 APPROVING THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
12
CORPORATE GOVERNANCE
Director Nomination Process
Our Nominating and Corporate Governance Committee is responsible for identifying individuals qualified to serve as directors, consistent with criteria approved by our board, and recommending such persons to be nominated for election as directors, except where we are legally required by contract, law or otherwise to provide third parties with the right to nominate.
The process followed by our Nominating and Corporate Governance Committee to identify and evaluate director candidates includes requests to members of the Board of Directors and others for recommendations, meetings from time to time to evaluate biographical information and background material relating to potential candidates, and interviews of selected candidates by management, recruiters, members of the committee, and our board. The qualifications, qualities, and skills that our Nominating and Corporate Governance Committee believes must be met by a committee-recommended nominee for a position on our Board of Directors include:
•The nominee shall have experience at a strategic or policymaking level in a business, government, non-profit or academic organization of high standing.
•The nominee shall be highly accomplished in his or her respective field, with superior credentials and recognition.
•The nominee shall be well regarded in the community and shall have a long-term reputation for their high ethical and moral standards.
•The nominee shall have sufficient time and availability to devote to the affairs of the Company, particularly in light of the number of boards of directors on which such nominee may serve.
•To the extent such nominee serves or has previously served on other boards, the nominee shall have a demonstrated history of actively contributing at board meetings.
Our articles contain certain “advance notice” provisions with respect to the election of our directors. These provisions are intended to: (i) facilitate orderly and efficient annual general meetings or, where the need arises, special meetings; (ii) ensure that all our shareholders receive adequate notice of board nominations and sufficient information with respect to all nominees; and (iii) allow our shareholders to vote on an informed basis. Only persons who are nominated by shareholders in accordance with our advance notice provisions will be eligible for election as directors at any Annual Meeting of our shareholders, or at any special meeting of our shareholders if one of the purposes for which the special meeting was called was the election of directors.
Under our advance notice provisions, a shareholder wishing to nominate a director would be required to provide us with notice, in a prescribed form and within prescribed time periods. These time periods include, (i) in the case of an Annual Meeting of Shareholders (including annual and special meetings), not less than thirty (30) days prior to the date of the Annual Meeting of Shareholders; provided that if the first public announcement of the date of the Annual Meeting of Shareholders, which we refer to as the notice date, is less than fifty (50) days before the meeting date, not later than the close of business on the tenth (10th) day following the notice date; and (ii) in the case of a special meeting (which is not also an Annual Meeting) of shareholders called for any purpose which includes electing directors, not later than the close of business on the fifteenth (15th) day following the notice date.
Director Independence
Our common shares are listed on the Nasdaq Global Select Market. Under the Nasdaq Stock Market LLC, or Nasdaq, Marketplace Rules, or the Nasdaq Listing Rules, independent directors must comprise a majority of a listed company’s Board of Directors. In addition, the Nasdaq Listing Rules require that, subject to specified exceptions, each member of a listed company’s audit, compensation and nominating and governance committees be independent. Audit committee members must also satisfy additional independence criteria, including those set forth in Rule 10A-3 under the Exchange Act, and compensation committee members must also satisfy the independence criteria set forth in Rule 10C-1 under the Exchange Act. Under the Nasdaq Listing Rules, a director will only qualify as an “independent director” if, in the opinion of that company’s Board of Directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3 under the Exchange Act, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the Board of Directors, or any other board committee: (i) accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries, other than compensation for board service; or (ii) be an affiliated person of the listed company or any of its subsidiaries. In order
13
to be considered independent for purposes of Rule 10C-1, the Board of Directors must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining whether a director has a relationship to such company which is material to that director’s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: the source of compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates.
Our Board of Directors has undertaken a review of the composition of our Board of Directors and its committees and the independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our Board of Directors has determined that Dr. Hayden, Dr. Quake, and Mr. Montalbano are independent directors, including for purposes of Nasdaq and the SEC rules. In making that determination, our Board of Directors considered the relationships that each director has with us and all other facts and circumstances the Board of Directors deemed relevant in determining independence, including the potential deemed beneficial ownership of our capital shares by each director, including non-employee directors that are affiliated with certain of our major shareholders. The composition and functioning of our Board of Directors and each of our committees complies with all applicable Nasdaq Listing Rules and the rules and regulations of the SEC.
Board Committees
Our Board of Directors has established an audit committee, a compensation committee, and a nominating and corporate governance committee, each of which operates pursuant to a charter adopted by our Board of Directors. The composition and functioning of all our committees comply with the applicable Nasdaq Listing Rules, SOX, and SEC rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. The full text of our audit committee charter, compensation committee charter, and nominating and corporate governance committee charter are posted on the investor relations portion of our website www.abcellera.com.
Audit Committee
Our audit committee is comprised of Mr. Montalbano, Dr. Quake, and Dr. Hayden, and is chaired by Mr. Montalbano. The functions of the audit committee include:
•recommending appointing and approving the compensation of, and assessing the independence of, our independent registered public accounting firm;
•pre-approving auditing and permissible non-audit services, and the terms of such services, to be provided by our independent registered public accounting firm;
•reviewing the overall audit plan with our independent registered public accounting firm and members of management responsible for preparing our financial statements;
•reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us;
•coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
•establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;
•recommending based upon the audit committee’s review and discussions with management and our independent registered public accounting firm whether our audited financial statements shall be included in our Annual Report on Form 10-K;
•monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to our financial statements and accounting matters;
•preparing the audit committee report required by SEC rules to be included in our annual proxy statement;
•reviewing material related person transactions for potential conflict of interest situations and approving such transactions;
•overseeing cybersecurity risk management program, including reviewing management reports on assessments, initiatives, and the effectiveness of incident response protocols;
•reviewing quarterly reports on Form 10-Q and earnings releases; and
14
•reviewing and discussing with management the Company’s risk register.
All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC, the Nasdaq Listing Rules. Our Board of Directors has determined that Mr. Montalbano qualifies as an “audit committee financial expert” within the meaning of applicable SEC regulations. In making this determination, our Board of Directors considered the nature and scope of experience that Mr. Montalbano has previously had with public reporting companies, including service as a Chief Executive Officer and Audit Committee Chair of other public and private companies. Our Board of Directors has determined that all directors that are members of our audit committee satisfy the relevant independence requirements for service on the audit committee set forth in the rules of the SEC, the Nasdaq Listing Rules and applicable Canadian laws. Both our independent registered public accounting firm and management will periodically meet privately with our audit committee.
Compensation Committee
Our compensation committee is comprised of Dr. Hayden and Mr. Montalbano and is chaired by Dr. Hayden. Each member of our compensation committee is a non-employee director, as defined in Rule 16b-3 promulgated under the Exchange Act. The functions of the compensation committee include:
•annually reviewing and recommending to the Board of Directors the corporate goals and objectives relevant to the compensation of our Chief Executive Officer;
•evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and based on such evaluation (i) reviewing and determining the cash compensation of our Chief Executive Officer and (ii) reviewing and approving grants and awards to our Chief Executive Officer under equity-based plans;
•reviewing and approving the compensation of our other executive officers;
•reviewing and establishing our overall management compensation, philosophy and policy;
•overseeing and administering our compensation and similar plans;
•evaluating and assessing potential and current compensation advisors in accordance with the independence standards identified in the applicable Nasdaq Listing Rules;
•reviewing and approving our policies and procedures for the grant of equity-based awards;
•reviewing and recommending to the Board of Directors the compensation of our directors;
•preparing our compensation committee report if and when required by SEC rules;
•reviewing and discussing annually with management our “Compensation Discussion and Analysis,” if and when required, to be included in our annual proxy statement; and
•reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation of compensation matters.
Nominating and Corporate Governance Committee
In 2025, our Nominating and Corporate Governance Committee consisted of Dr. Hayden and Mr. Montalbano, and was chaired by Dr. Lo. Effective November 6, 2025, Dr. Quake replaced Dr. Lo as Chairman of the Nominating and Corporate Governance Committee. The functions of the committee include:
•developing and recommending to the Board of Directors criteria for board and committee membership;
•establishing procedures for identifying and evaluating Board of Director candidates, including nominees recommended by shareholders;
•reviewing the composition of the Board of Directors to ensure that it is composed of members containing the appropriate skills and expertise to advise us;
•identifying individuals qualified to become members of the Board of Directors;
•recommending to the Board of Directors the persons to be nominated for election as directors and to each of the board’s committees;
•developing and recommending to the Board of Directors a code of business conduct and ethics and a set of corporate governance guidelines; and
15
•overseeing the evaluation of our Board of Directors.
The Nominating and Corporate Governance Committee considers candidates for Board of Directors membership suggested by its members and the Chief Executive Officer. Additionally, in selecting nominees for directors, the Nominating and Corporate Governance Committee will review candidates recommended by shareholders in the same manner and using the same general criteria as candidates recruited by the committee and/or recommended by our Board of Directors. Any shareholder who wishes to recommend a candidate for consideration by the committee as a nominee for director should follow the procedures described later in this proxy statement under the heading “Shareholder Proposals.” The Nominating and Corporate Governance Committee will also consider whether to nominate any person proposed by a shareholder in accordance with the provisions of our articles relating to shareholder nominations as described later in this proxy statement under the heading “Shareholder Proposals.”
Identifying and Evaluating Director Nominees. Our Board of Directors is responsible for filling vacancies on our Board of Directors and for nominating candidates for election by our shareholders each year in the class of directors whose term expires at the relevant Annual Meeting. The Board of Directors delegates the selection and nomination process to the Nominating and Corporate Governance Committee, with the expectation that other members of the Board of Directors and management will be requested to participate in the process as appropriate.
Generally, the Nominating and Corporate Governance Committee identifies candidates for director nominees in consultation with management, using search firms or other advisors, through the recommendations submitted by shareholders or through such other methods as the Nominating and Corporate Governance Committee deems to be helpful to identify candidates. Once candidates have been identified, the Nominating and Corporate Governance Committee confirms that each candidate meets all the minimum qualifications for director nominees established by the Nominating and Corporate Governance Committee. The Nominating and Corporate Governance Committee may gather information about the candidates through interviews, detailed questionnaires, comprehensive background checks or any other means that the Nominating and Corporate Governance Committee deems to be appropriate in the evaluation process. The Nominating and Corporate Governance Committee then meets as a group to discuss and evaluate each candidate’s qualities and skills, both individually and in light of the overall composition and needs of our Board of Directors. Based on the results of the evaluation process, the Nominating and Corporate Governance Committee recommends candidates for the Board of Directors’ approval to fill a vacancy or as director nominees for election to the Board of Directors by our shareholders each year in the class of directors whose term expires at the relevant Annual Meeting.
Board and Committee Meetings Attendance
The full Board of Directors met five (5) times in 2025. Each member of the Board of Directors attended in person or participated in 75% or more of the aggregate of (i) the total number of meetings of the Board of Directors (held during the period for which such person has been a director) and (ii) the total number of meetings held by all committees of the Board of Directors on which such person served (during the periods that such person served). The Company’s Compensation Committee met six (6) times in 2025, each member of the Compensation Committee attended all meetings. The Company’s Audit Committee met four (4) times in 2025, each member of the Audit Committee attended all meetings. The Company’s Nominating and Corporate Governance Committee met twice (2) in 2025, each member of the Company’s Nominating and Corporate Governance Committee attended the meeting.
Policy on Trading and Hedging of Company Shares
Certain transactions involving our securities (such as purchases and sales of publicly traded put and call options and short sales) create heightened compliance risks or could create the appearance of misalignment between management and shareholders. We maintain an Insider Trading Compliance Policy that expressly prohibits our executive officers, directors, and designated employees and consultants from engaging in certain prohibited transactions, including short sales, purchases, or sales of derivative securities or hedging transactions. While the policy does not apply directly to the Company's repurchases of securities, a repurchase would be made either during an open trading window or pursuant to a written trading plan adopted in accordance with Rule 10b5-1 under the Exchange Act. Any such Rule 10b5-1 plan must be established during an open trading window, when the Company is not in possession of material, nonpublic information.
Timing of Equity Grants
16
Clawback Policy
We maintain a clawback policy in accordance with the SEC and Nasdaq requirements under the Dodd-Frank Wall Street Reform and Consumer Protection Act. Under the policy, if the Company is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws, certain incentive-based compensation paid or awarded to covered executives will be subject to reduction and/or repayment if the amount of such compensation was calculated based on the achievement of financial results that were the subject of the restatement and the amount of such compensation that would have been received by the covered executives had the financial results been properly reported would have been lower than the amount actually awarded.
Code of Business Conduct and Ethics
We have adopted a written code of business conduct and ethics that applies to our employees, officers (including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions), agents and representatives, including directors and consultants. A current copy of the code is posted in the Investor Relations section of our website at www.abcellera.com. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form 8-K.
Board’s Role in Risk Oversight
Board Leadership Structure
The Board of Directors believes that, currently, it is in the best interest of the Company and its shareholders to combine the roles of Chairperson and Chief Executive Officer. However, there is no formal policy regarding the combination or separation of these roles. The Board of Directors believes that Dr. Hansen’s leadership in the field and daily involvement in managing the Company as the Chief Executive Officer make him best suited to also serve as Chairperson and guide the Board of Directors in setting priorities and addressing risks and challenges.
Risk Oversight
Risk is inherent to every business, and how well a company manages risk can ultimately determine its success. We face several risks, including risks relating to our financial condition, development and commercialization activities, operations, strategic direction, cybersecurity, intellectual property, and geopolitical risks as more fully discussed in the filings we make with the SEC. Management is responsible for the day-to-day management of the risks we face, while our Board of Directors, as a whole and through its committees, is responsible for oversight of risk management. In its risk oversight role, our Board of Directors is responsible for satisfying itself that the risk management processes designed and implemented by management are adequate and functioning as intended.
The Board of Directors' oversight of the management of our risks is conducted primarily through committees of the Board, as disclosed in the descriptions of each committee below and in each committee's charter. The full Board of Directors (or the appropriate board committee, in the case of risks under the purview of a particular committee) discusses with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing the management of a particular risk or risks, the chairperson of the relevant committee reports on the discussion to the full Board of Directors during the committee reports portion of the next board meeting. This enables the Board of Directors and its committees to coordinate the risk oversight role, particularly with respect to risk interrelationships.
Communication with our Board of Directors
Any interested party with concerns about our Company may report such concerns to the Board of Directors or the lead director of our Board of Directors and Nominating and Corporate Governance Committee, by submitting a written communication to the attention of such director at the following address:
c/o AbCellera Biologics Inc.
150 W 4th Avenue
Vancouver, BC V5Y 1G6
17
You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a shareholder or other interested party.
A copy of any such written communication may also be forwarded to our Chief Legal Officer, and a copy of such communication may be retained for a reasonable period. Any director may discuss the matter with our Chief Legal Officer, outside legal counsel, independent advisors, with non-management directors, or with our management, or may take other action or no action as the director determines in good faith, using reasonable judgment, and applying his or her own discretion.
Communications may be forwarded to other directors if they relate to important substantive matters and include suggestions or comments that other directors should know. In general, communications relating to corporate governance and long-term corporate strategy are more likely to be forwarded than communications relating to ordinary business affairs, personal grievances, or matters for which we tend to receive repetitive or duplicative communications.
The Audit Committee oversees the procedures for the receipt, retention, and treatment of complaints received by our company regarding accounting, internal accounting controls, or audit matters, and the confidential, anonymous submission by employees of concerns regarding questionable accounting, internal accounting controls or auditing matters. We have also established a toll-free telephone number for the reporting of such activity, which is +1 (877) 458-7914.
Board and Committee Evaluations
The Nominating and Corporate Governance Committee oversees the annual board and committee evaluation process. Generally, the Board of Directors and each committee conduct self-evaluations through various means. Responses are summarized and provided to the Board of Directors and each committee at their meetings to facilitate the Board of Directors and each committee's examination and discussion of the effectiveness of the board and committees, the Board of Directors and committee structure and dynamics, and areas for possible improvement. The Nominating and Corporate Governance Committee establishes the Board of Directors and committee evaluation process each year and may, from time to time, determine to use an independent third-party evaluation process.
18
DIRECTOR COMPENSATION
Non-Employee Director Compensation Policy
Our Board of Directors utilizes a non-employee director compensation policy. The policy is designed to enable us to attract and retain highly qualified non-employee directors on a long-term basis. Under the policy, our non-employee directors will be eligible to receive cash retainers (which will be prorated for partial years of service) and equity awards as set forth below:
| Annual Retainer for Board Membership | ||||||||
| Annual service on the Board of Directors | $ | 50,000 | ||||||
| Additional retainer for annual service as non-executive chairperson or lead director of the Board of Directors | $ | 30,000 | ||||||
| Additional Annual Retainer for Committee Membership | ||||||||
| Annual service as audit committee chairperson | $ | 20,000 | ||||||
| Annual service as member of the audit committee (other than chair) | $ | 10,000 | ||||||
| Annual service as compensation committee chairperson | $ | 15,000 | ||||||
| Annual service as member of the compensation committee (other than chair) | $ | 7,500 | ||||||
| Annual service as nominating and corporate governance committee chairperson | $ | 10,000 | ||||||
| Annual service as member of the nominating and corporate governance committee (other than chair) | $ | 5,000 | ||||||
In addition, our policy provides that, upon initial election or appointment to our Board of Directors, each new non-employee director will be granted a one-time grant of a non-statutory share option to purchase our common shares with an aggregate targeted grant date fair value of $600,000 on the date of such director’s election or appointment to the Board of Directors, or the Director Initial Grant. The Director Initial Grant will vest in substantially equal annual installments over three years, subject to the non-employee director’s continued service to the Board of Directors through each such vesting date. On the date of each Annual Meeting of Shareholders of our company, each non-employee director who will continue as a non-employee director following such meeting will be granted an annual award of a non-statutory share option to purchase our common shares with an aggregate targeted grant date fair value of $400,000, or the Director Annual Grant. The Director Annual Grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next Annual Meeting of Shareholders, subject to the non-employee director’s continued service to the Board of Directors through each such vesting date. For Director initial election or appointment and annual awards, the volume-weighted average price of a share of our common stock (the “Average VWAP”) for the 60 trading days preceding the grant date of the equity awards is used in determining the number of equity awards to grant. The Director Initial Grant and Director Annual Grant are subject to full acceleration of vesting upon the sale of our company.
We reimburse all reasonable out-of-pocket expenses incurred by directors for their attendance at meetings of our Board of Directors or any of its committees.
Employee directors will receive no additional compensation for their service as a director.
19
Non-Employee Director Compensation Table
The following table provides information regarding the total compensation that was earned by or paid to each of our non-employee directors during the fiscal year ended December 31, 2025. Dr. Hansen, who is our Chief Executive Officer and President, and Dr. Lecault, who is our Chief Technology Officer, did not receive any additional compensation for their services as director. The compensation received by Drs. Hansen and Lecault, as NEOs of our company, is presented in “Executive Compensation—2025 Summary Compensation Table” below.
| Name | Fees Earned or Paid in Cash ($)(1) | Option Award ($)(2) | All Other Compensation ($) | Total ($) | ||||||||||||||||||||||
Michael Hayden, MBCHB (M.D.), Ph.D.(3) | 110,000 | 476,361 | — | 586,361 | ||||||||||||||||||||||
John S. Montalbano, CFA(4) | 82,500 | 476,361 | — | 558,861 | ||||||||||||||||||||||
Andrew Lo, Ph. D.(5) | 59,425 | 476,361 | — | 535,786 | ||||||||||||||||||||||
Stephen R. Quake, D.Phil.(6) | 10,575 | 426,916 | — | 437,491 | ||||||||||||||||||||||
__________________________
(1)Amounts paid reflect fees earned for 2025 service and are made pursuant to the Amended and Restated Non-Employee Director Compensation policy, effective as of February 23, 2021.
(2)The amounts reported represent the aggregate grant date fair value of the stock options granted to our directors during the 2025 fiscal year, calculated in accordance with ASC Topic 718. Such grant date fair values do not consider any estimated forfeitures. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 10 of our Consolidated Financial Statements included in our annual report on Form 10-K for the year ended December 31, 2025. The amounts reported in this column reflect the accounting cost for these stock options and do not correspond to the actual economic value that may be received by our directors upon the exercise of the stock options or any sale of the underlying common shares.
(3)As of December 31, 2025, Dr. Hayden held outstanding options to purchase an aggregate of 629,843 shares of Company common shares.
(4)As of December 31, 2025, Mr. Montalbano held outstanding options to purchase an aggregate of 1,029,843 shares of Company common shares.
(5)Effective November 6, 2025, Dr. Lo retired from the Board of Directors. Dr. Lo’s cash compensation reported in the table above is prorated for 2025 service and his equity awarded in 2025 following the 2025 Annual General Meeting was forfeited. As of December 31, 2025, Dr. Lo held outstanding options to purchase an aggregate of 302,490 shares of Company common shares.
(6)Effective November 6, 2025, Dr. Quake was appointed to the Board of Directors. Dr. Quake’s compensation reported in the table above is prorated for 2025 service and includes the new Director equity grant. As of December 31, 2025, Dr. Quake held outstanding options to purchase an aggregate of 194,932 shares of Company common shares.
20
EXECUTIVE COMPENSATION
Compensation Discussion & Analysis
Overview
The following discussion contains forward-looking statements that are based on our current plans and expectations regarding our future compensation programs. The actual amount and form of compensation that we pay and the compensation policies and practices that we adopt in the future may differ materially from the currently planned programs that are summarized in this discussion.
The compensation provided to our named executive officers for the fiscal years ended December 31, 2023, 2024, and 2025, is detailed in the 2025 Summary Compensation Table and accompanying footnotes, narrative, and tables that follow. Our named executive officers for the fiscal year ended December 31, 2025, which consists of our Chief Executive Officer, our Chief Financial Officer, and our two other executive officers, who served as executive officers throughout all of 2025, are:
•Carl L.G. Hansen, Ph.D., our Chief Executive Officer;
•Andrew Booth, our Chief Financial Officer;
•Véronique Lecault, Ph.D., our Chief Technology Officer; and
•Tryn Stimart, our Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer.
21
2025 Corporate Performance Highlights
We have made significant advancements executing on our long-term strategy by using our discovery and development capabilities to transition into a clinical-stage biotechnology company with an internal pipeline of AbCellera-owned drug assets. We achieved several critical milestones that validated our vertically-integrated platform and shifted our focus toward building long-term value through proprietary medicine development. In 2025, we successfully advanced our first two internal drug candidates into clinical development: ABCL635, a potential first-in-class non-hormonal treatment for vasomotor symptoms (“VMS”), and ABCL575, a potential medicine for the treatment of atopic dermatitis and other inflammation and immunology conditions, into clinical trials following the receipt of No Objection Letters from Health Canada.
In 2025, we accomplished the following key items that support our mission and goals:
•Initiated Phase 1/2 clinical trial of ABCL635 in a randomized, placebo-controlled, double-blind study in healthy men and postmenopausal women with or without VMS.
•Initiated Phase 1 clinical trial of ABCL575 in a randomized, placebo-controlled, double-blind study to assess safety and tolerability in healthy participants following subcutaneous doses.
•Continued to build upon our internal pipeline by nominating development candidates ABCL688 and ABCL386 for autoimmune and oncology indications, respectively.
•Substantially completed major platform investments, including the completion of construction on our 130,000-square-foot clinical manufacturing facility in Vancouver.
•Reached a cumulative total of 19 molecules in the clinic across oncology, infectious disease, neurology, animal health, immunology, dermatology, and gastrointestinal disease.
•Closed the year with approximately $700 million in available liquidity to continue to execute on our strategy.
Key Compensation Decisions and Actions
Our Compensation Committee took the following decisions and actions in 2025 related to our NEO compensation:
| Compensation Area | Highlights | |||||||
| Cash Compensation | •Updated target base salaries for our NEOs | |||||||
| Equity Compensation | •Maintained target NEO annual stock award grant and timing | |||||||
| Process & Governance | •Updated the peer group of comparable companies | |||||||
•Continued engagement with Alpine Rewards as the Compensation Committee’s independent advisor | ||||||||
Key Compensation Governance Attributes
The Compensation Committee believes that our executive compensation program must be underpinned by sound practices and processes that align with our compensation philosophy, objectives, and bolster our overall governance and risk management framework. A summary of these key features includes:
•Providing a majority of compensation in long-term incentives that have multi-year vesting schedules,
•No history of option repricing or backdating,
•No hedging of Company shares,
•No use of Company securities as collateral without Board approval if loan exceeds 20% of pledged securities,
•Providing a competitive mix of fixed (e.g., base salary) and variable (e.g., bonus) compensation,
•Establishing a relevant peer group to serve as market comparator for key compensation metrics,
•Not guaranteeing salary increases or bonuses,
•Limiting executive perquisites, and no defined benefit pension plans or other post-employment benefit plans, and
•Consulting with an independent compensation consultant.
22
“Say-on-Pay” Vote on Executive Compensation
At our 2025 Annual Meeting of Shareholders, we received approximately 88% approval for our annual advisory “Say-on-Pay” vote to approve the compensation of our NEOs. We believe this vote is indicative of strong support for our pay programs and their general design. Accordingly, our Compensation Committee maintained the general structure of our pay programs for 2025.
23
APPROACH TO COMPENSATION
Our Philosophy
At AbCellera, we believe that great and enduring companies are built by strong teams of exceptional people. We believe a strong corporate culture is essential for the recruitment, development, and retention of exceptional employees and teams. For this reason, we believe our long-term success depends on our ability to attract and train top talent. We see talent and team development as an opportunity to build a competitive advantage that amplifies every dimension of our business. We see investments in our people as essential to the success of our Company.
Building a winning culture requires investment and continuous diligent effort. Our executive compensation program is aligned with the pillars of our culture and our long-term vision.
We accomplish these goals by taking a holistic view of compensation. We aim to offer total compensation that is competitive for each role, based on market data for local, regional, or global conditions, as appropriate. In addition to competitive salaries, equity awards, and performance bonuses, our compensation includes comprehensive healthcare benefits, fitness and active-lifestyle benefits, and retirement-savings contributions. We do not target a specific mix of compensation, although we deliver a majority of compensation through long-term incentives and aim to be particularly competitive with regard to equity-based long-term incentives. We do this because we believe that shared ownership promotes employee retention and aligns with the long-term success of our Company.
To attract and retain qualified executives, we seek to provide our NEOs with target pay opportunities that are competitive within our industry. Our comparative framework uses peer companies in the life sciences industry with a similar business and financial profile, and broader, size-appropriate comparisons in the life sciences industry as a secondary market. We target base salary and cash bonuses at the fiftieth (50th) percentile of the market and recognize that individuals are compensated at the range appropriate for the role within the market based on individual performance, Company performance, and the criticality of the role, over time. Further, in alignment with our philosophy, long term incentives are again commensurate with performance and the role and impact on the Company's success, targeting a range between the 50-75th percentile.
Process and Roles
Role of the Compensation Committee. Our Compensation Committee is responsible for establishing and overseeing our executive compensation program. Specific responsibilities of the Compensation Committee can be found in the “Corporate Governance” section of this proxy statement. The Compensation Committee reviews our NEO compensation packages on an annual basis or more frequently as it deems appropriate. In its review process, the Compensation Committee discusses with our Chief Executive Officer proposed compensation for all NEOs other than himself. Following the Compensation Committee’s discussions with our Chief Executive Officer, and in consideration of all information provided by the Compensation Committee’s independent consultant and management, the Compensation Committee approves each NEO’s compensation for the upcoming fiscal year, including the performance measures and objectives to be used for purposes of determining their annual cash bonuses for the fiscal year. In addition, the Compensation Committee evaluates the performance of the Company, and the Chief Executive Officer assesses the individual performance of each executive officer, except himself, to determine whether to pay cash bonuses for the previous fiscal year and, if so, the amount of any such bonuses.
Role of our Chief Executive Officer and Other Management Members. Our Chief Executive Officer evaluates and reviews with the Compensation Committee the individual performance and contributions of each of the other NEOs and makes recommendations to the Compensation Committee regarding base salary, short-term incentive awards, and long-term incentive awards. The Compensation Committee reviews and considers such recommendations, but ultimately retains full discretion and authority over the final compensation decisions for the NEOs. Our Chief Executive Officer also recommends the Company performance objectives that are used to determine bonus amounts of the other NEOs and consults with select members of management in the development of the Company goals and individual performance goals. The Compensation Committee may request that certain executives attend portions of Compensation Committee meetings based on the topics being covered and their respective areas of expertise. NEO compensation decisions are made in executive session without the respective NEOs present.
Role of our Independent Compensation Consultant. Our Compensation Committee is authorized to engage a compensation consultant or other advisors to review our executive officers’ compensation, including an analysis against the compensation of executive officers at comparable companies, to ensure that our compensation is market competitive, with the goal of retaining and adequately motivating our senior management. Throughout 2025, our Compensation Committee continued to engage Alpine Rewards as its independent compensation consultant to make recommendations for updating our compensation peer group and to review and make recommendations regarding our executive and director
24
compensation. Alpine Rewards did not provide services to us other than the services to our Compensation Committee described herein during 2025. Our Compensation Committee performs an annual assessment of its compensation consultant’s independence to determine whether the consultant is independent and throughout 2025 determined that Alpine Rewards is independent pursuant to the listing standards of the relevant Nasdaq and SEC rules and has determined that no conflict of interest has arisen as a result of the work performed.
Use of Market Data
The Compensation Committee makes use of various external and internal references in making its decisions. One of these references is external compensation market data related to our NEOs. The Compensation Committee engaged Alpine Rewards to develop a peer group for use in evaluating the competitiveness of NEO compensation arrangements for 2025. Alpine Rewards developed a group of 20 companies that are comparable to AbCellera. The criteria used to select these companies were as follows:
| Element | 2025 Criteria | |||||||
Business | •Public, US/Canada-based biotechnology/life sciences companies, with a focus on those that use a technology platform, as well as immunology and metabolic focuses | |||||||
| Revenue | •Trailing twelve-month revenues generally under $150M to reflect companies of similar scale as AbCellera, while allowing room for potential growth | |||||||
| Market Capitalization | •Market capitalization in the range of 0.3x to 3x AbCellera (or approximately between $0.3B and $3B) | |||||||
| Organizational Complexity | •Companies with generally between 150 and 1,500 employees | |||||||
In October 2024, the Compensation Committee endorsed the following peer group for 2025:
Absci | Nurix Therapeutics | Structure Therapeutics | ||||||
| Adaptive Biotechnologies | Prime Medicine | Verve Therapeutics | ||||||
| Agios Pharmaceuticals | Recursion Pharmaceuticals | Vir Biotechnology | ||||||
| Allogene Therapeutics | Regenxbio | Xencor | ||||||
Arcutis Biotherapeutics | Relay Therapeutics | Xenon Pharmaceuticals | ||||||
Entrada Therapeutics | Sana Biotechnology | Y-mAbs Therapeutics | ||||||
| Ligand Pharmaceuticals | Spyre Therapeutics | |||||||
In addition to market compensation data, the Compensation Committee also reflects on the following, as appropriate, in their decision-making process:
•The Company’s vision, mission, strategies, and corporate goals
•The compensation philosophy and objectives
•Company performance and outlook
•Broader market compensation information and data
•Labor market trends and dynamics
•Individual NEO roles, performance, and contributions
•Compensation histories for individual NEOs
25
Compensation Program and Decisions
Compensation for our NEOs is comprised primarily of the following four main components:
| Element | Summary Purpose | |||||||
| Base Salary | •Provide a fixed source of income commensurate with the NEO’s position at the Company | |||||||
| Annual Cash Incentive Bonus | •Challenge NEOs with bold and ambitious goals to help the company achieve the best possible financial and operational results | |||||||
•Reward teamwork, accountability, excellence, and progress towards AbCellera’s business strategy | ||||||||
•Recognize outstanding contributions that go above and beyond | ||||||||
| Element | Summary Purpose | |||||||
| Long-Term Equity Incentives | •Align efforts and interests to amplify long-term value for patients, partners, and shareholders | |||||||
•Attract and retain NEOs who believe in and are motivated by our long-term vision | ||||||||
| Benefits | •Provide our NEOs with extended health benefits to maximize their wellbeing | |||||||
•Provide peace of mind with retirement benefits, life insurance as well as certain protections if we encounter a change in control or separation event | ||||||||
•Foster growth, learning and development to realize the full potential of each NEO | ||||||||
26
Annual Base Salaries
Base salaries are determined on a case-by-case basis for each NEO, including consideration of each NEO’s experience, expertise, and performance, as well as market compensation levels for similar positions. Base salaries for our NEOs are established at the time of hire, considering the NEO’s position and qualifications and approval of the Compensation Committee. Generally, our Compensation Committee reviews and evaluates our NEO’s base salaries each year, with input from our Chief Executive Officer (other than with respect to himself). The Compensation Committee takes into consideration the NEO’s performance, contributions, market base salary data, changes in the scope of role, overall labor market conditions, and the overall development of our company utilizing input from the Chief Executive Officer (other than with respect to himself), as well as the factors described in the “Approach to Compensation” section above.
The following table presents the base salaries for each of our NEOs for the years 2024 and 2025, as approved by our Compensation Committee.
| 2024 Annualized Base Salary ($) | 2025 Annualized Base Salary ($)(1) | % Change | Nature of Changes | |||||||||||||||||||||||
Carl L.G. Hansen, Ph.D. Chief Executive Officer | 460,000 | 550,000 | 19.6 | % | Market Adjustment(2) | |||||||||||||||||||||
Andrew Booth Chief Financial Officer | 460,000 | 485,000 | 5.4 | % | Market Adjustment | |||||||||||||||||||||
Véronique Lecault, Ph.D. Chief Technology Officer | 460,000 | 454,000 | (1.3) | % | Market Adjustment | |||||||||||||||||||||
Tryn Stimart Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer | 460,000 | 470,000 | 2.2 | % | Market Adjustment | |||||||||||||||||||||
(1) For Canadian resident executives, base salary is paid in Canadian dollars. The 2024 and 2025 base salary is translated here into USD using the 2024 and 2025 weighted-average exchange ratio of CAD CAD $1.370:USD $1.00 and CAD $1.40:USD $1.00, respectively, as set forth by the Bank of Canada. The decrease in salary disclosed for Dr. Lecault’s salary is due to foreign exchange conversion.
(2)As part of the 2025 compensation review, it was noted that our CEO's base salary was significantly below the market. The Committee agreed to a multi-year strategy to align the salary more closely with our comparable peer companies.
Annual Cash Incentive Bonus
AbCellera has a formal short-term incentive program that is designed to challenge NEOs with bold and ambitious goals to help the Company achieve the best possible financial and operational results, reward team performance, accountability, excellence and progress towards AbCellera’s business strategy, and recognize outstanding contributions that go above and beyond. The program goals are intended to be measured over one year but may be accomplished at certain times during the program year. The payouts under the program are cash-based, as is customary in our industry. Under our bonus program, each NEO has a target bonus opportunity, defined as a percentage of his or her annualized base salary. The target amounts are initially set at the time of hire based on the individual’s role and level in the organization. These bonus targets are subject to adjustment each year based on the competitive market and our internal compensation levels and structure. The general design of our bonus program is as follows:
whereas the Bonus Multiplier is calculated as follows to recognize both components of teamwork and individual accountability:
In November 2024, our Compensation Committee reviewed the target bonus opportunities of each of our executive officers, including each of our NEOs, and set the target bonus percentage for each such NEO as set forth in the table below
27
effective January 1, 2025. In 2025, the target bonus percentage and weighting metrics for each of our NEOs remained unchanged.
| 2025 Annualized Base Salary ($) | 2025 Target Bonus Percentage | Corporate Achievements Weight | Individual Contribution Weight | |||||||||||||||||||||||
Carl L.G. Hansen, Ph.D. Chief Executive Officer | 550,000 | 65 | % | 100 | % | N/A | ||||||||||||||||||||
Andrew Booth Chief Financial Officer | 485,000 | 45 | % | 70 | % | 30 | % | |||||||||||||||||||
Véronique Lecault, Ph.D. Chief Technology Officer | 454,000 | 45 | % | 70 | % | 30 | % | |||||||||||||||||||
Tryn Stimart Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer | 470,000 | 45 | % | 70 | % | 30 | % | |||||||||||||||||||
In January 2025, the Board of Directors approved the 2025 corporate goals, and these were used to assess our corporate performance in 2025. The Compensation Committee believes that each of these goals is strongly aligned to the creation of shareholder value.
The 2025 performance goals were aggressive and set as stretch goals to challenge our NEOs such that the attainment of executive target annual cash incentive bonus opportunities was not assured at the time they were set and would require a high level of effort and execution on the part of the executive officers and others to achieve the goals. The Compensation Committee assessment also considered achievements that were not included in the original goals but brought significant value to the company.
The specific corporate performance goals established for 2025 are set forth below:
28
| 2025 Corporate Goals | |||||
Pipeline | For both ABCL635 and ABCL575, submit Clinical Trial Applications (CTAs), the Canadian equivalent to an Investigational New Drug (IND) submission, obtain No Objection Letters from Health Canada, and commence Phase 1 clinical trials in Canada. Nominate two development candidates to move forward into IND enabling studies. | ||||
| Platform | Complete build of the manufacturing facility and successfully complete a shakedown run. Successfully complete new Enterprise Resource Planning ("ERP") system implementation for manufacturing capabilities. | ||||
| Financial Performance | Maintain strong liquidity position and operational efficiency. Complete major capital investments our platform. | ||||
In light of our good performance and the challenging nature of the goals, the Compensation Committee, in its judgment, determined our corporate performance percentage to be 100% of the target performance level for 2025, based on the following assessment:
| 2025 Corporate Goals | Highlights | Assessment | ||||||||||||
Pipeline | For ABCL635 and ABCL 575, CTAs were submitted, No Objection letters received, and first patients dosed on August 7, 2025 and August 27, 2025, respectively. Nominated ABCL688, a potential first-in-class antibody medicine for autoimmune conditions, and ABCL386, a potential first-in-class antibody medicine for oncology, as development candidates. Started eight partner-initiated programs with downstreams and reached a cumulative total of 19 molecules into the clinic. | Met or exceeded most goals | ||||||||||||
| Platform | Manufacturing facility build and shakedown run completed. Facility ready for engineering runs. Successful implementation and go-live of new ERP system in the third quarter of 2025. | Met or exceeded most goals | ||||||||||||
| Financial Performance | Approximately $700 million in available liquidity as of December 31, 2025, to continue executing on our strategy. Substantially completed multi-year capital platform investments. | Met most goals | ||||||||||||
29
Based on the Compensation Committee’s evaluation of the annual cash incentive bonus goals, and the CEO’s assessment of individual contributions, the Compensation Committee approved the following bonus payments to our NEOs:
2025 Base Salary ($)(1) | 2025 Target Bonus Percentage | Target Incentive ($) | Corporate Performance Weight | Corporate Performance Percentage | Individual Performance Weight | Individual Performance Percentage | Bonus Multiplier | Annual Cash Incentive Award ($)(1) | ||||||||||||||||||||||||||||||||||||||||||||||||
Carl L.G. Hansen, Ph.D. Chief Executive Officer | 550,000 | 65 | % | 357,500 | 100 | % | 100 | % | N/A | N/A | 100 | % | 357,500 | |||||||||||||||||||||||||||||||||||||||||||
Andrew Booth Chief Financial Officer | 485,000 | 45 | % | 218,250 | 70 | % | 100 | % | 30 | % | 100 | % | 100 | % | 218,250 | |||||||||||||||||||||||||||||||||||||||||
Véronique Lecault, Ph.D. Chief Technology Officer | 454,000 | 45 | % | 204,300 | 70 | % | 100 | % | 30 | % | 100 | % | 100 | % | 204,300 | |||||||||||||||||||||||||||||||||||||||||
Tryn Stimart Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer | 470,000 | 45 | % | 211,500 | 70 | % | 100 | % | 30 | % | 100 | % | 100 | % | 211,500 | |||||||||||||||||||||||||||||||||||||||||
__________________________
(1)Base salary for all executives is determined in USD. For Canadian resident executives, base salary and bonus is paid in Canadian dollars. The 2025 base salary and bonus amounts are translated here into USD using the 2025 weighted-average exchange ratio of CAD $1.40:USD $1.00 as set forth by the Bank of Canada. Differences between the bonus amounts disclosed in the table above and the Summary Compensation Table are due to foreign exchange conversions.
Long-term incentives
Long-term incentives represent a key element in our overall compensation program and help us achieve a number of our critical compensation program goals:
•Align efforts and interests to amplify long-term value for patients, partners, and shareholders.
•Attract and retain NEOs who believe in and are motivated by our long-term vision.
•Reward teamwork, accountability, and excellence consistent with AbCellera’s performance.
Based on our key compensation program objectives and the general competitive market landscape, the Compensation Committee elects to grant 100% options for ongoing awards to existing NEOs (e.g., Drs. Hansen and Lecault, and Messrs. Booth and Stimart). The Compensation Committee expects to review the long-term incentive program each year and determine if changes are needed based on the growth and maturity of our company, any changes to our program objectives or philosophy, or changes in competitive market dynamics. The Compensation Committee typically approves equity grants for NEOs at the start of their employment and annually thereafter in connection with the annual performance review. Additionally, the Compensation Committee may periodically grant additional equity awards based on changes in job responsibility, performance and contribution, or other special circumstances.
The exercise price of all stock options equals the fair market value of our common shares on the date of grant. Prior to exercising a stock option, the holder has no shareholder rights with respect to the shares subject to the option, including no voting rights and no right to receive dividends or dividend equivalents. The vesting schedules for executive stock option grants are generally as follows:
•Stock option grant upon hire: vests twenty-five percent (25%) after one year, and the remaining portion of the grant vests monthly over the following thirty-six (36) months.
•Annual stock option grant: vests twenty-five percent (25%) after one year, and the remaining portion of the grant vests monthly over the following thirty-six (36) months.
In each case, vesting of each installment of these awards is subject to the grantee’s continued employment or service with the Company or one of our subsidiaries through each applicable vesting date.
In determining annual long-term incentive grants for NEOs, the Compensation Committee reviews market data for annual long-term incentive grant levels and groups the NEOs accordingly, and considers the factors described in the “Approach to Compensation” section above. The Compensation Committee generally endeavors to provide awards that are competitive with our peer group. In November 2024, the Compensation Committee approved the grants of stock options under our
30
2020 Share Option and Incentive Plan, or the 2020 Plan, to each of our NEOs that were awarded in January 2025. The following table sets forth the number of shares of common stock issuable upon exercise of the stock options granted to our NEOs in 2025:
| Named Executive Officer | Number of Stock Options Granted (#) | Exercise Price ($) | ||||||||||||
| Carl L.G. Hansen, Ph.D. | 2,730,109 | 2.93 | ||||||||||||
| Andrew Booth | 1,352,054 | 2.93 | ||||||||||||
| Véronique Lecault, Ph.D. | 832,033 | 2.93 | ||||||||||||
| Tryn Stimart | 832,033 | 2.93 | ||||||||||||
Severance and Change of Control Benefits
Our NEOs are entitled to certain benefits if an executive’s employment terminates in certain circumstances or if a change of control occurs. We believe that such benefits are an important component of each NEO’s overall compensation, as they help us attract and retain our key executives who may have other job alternatives that appear more attractive absent these protections. If any payment or other benefit provided to an NEO constitutes an “excess parachute payment” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended, the Code, and would be subject to an excise tax imposed by Section 4999 of the Code, then the amounts actually paid to that NEO will be reduced to the extent that such a reduction would result in the NEO receiving a greater amount than he or she would have received if the payment had been made in full. Each NEO’s right to receive these severance benefits is subject to his or her providing a release of claims in favor of us. These benefits are further described under the “Estimated Payments and Benefits Upon Termination or Change of Control” section of this proxy statement.
Benefits
We maintain a retirement plan featuring Registered Retirement Savings Plan, or RRSP, contributions for our Canadian employees and executives, and 401(k) contributions for our American employees and executives.
Our NEOs are also eligible to participate in all our employee benefit plans, including medical, dental, long-term disability, and term life insurance, on the same basis as other employees. We do not sponsor any qualified or non-qualified defined benefit or deferred compensation plans for any of our employees, including NEOs.
Compensation Risk Assessment
We believe that although a portion of the compensation provided to our executive officers and other employees is performance-based, our executive compensation program does not encourage excessive or unnecessary risk taking. Our compensation programs are designed to encourage our executive officers and other employees to remain focused on long-term strategy while being accountable to short-term goals, in connection with our compensation philosophy. As a result, we do not believe that our compensation programs are reasonably likely to have a material adverse effect on us.
To maintain flexibility in compensating our executive officers in a manner designed to promote our short- and long-term corporate goals, the Compensation Committee has not adopted a policy requiring all compensation to be deductible. The Compensation Committee believes that our shareholders’ interests are best served if its discretion and flexibility in awarding compensation are not restricted, thereby allowing such compensation to be consistent with the goals of our executive compensation program, even though some compensation awards may result in non-deductible compensation expense.
We follow the Financial Accounting Standard Board’s Accounting Standards Codification Topic 718, or FASB ASC Topic 718, for our stock-based compensation awards. FASB ASC Topic 718 requires us to measure the compensation expense for all share-based payment awards made to our employees and non-employee members of our Board of Directors, including stock options to purchase shares of our common stock and other stock awards, based on the grant date “fair value” of these awards. This calculation is performed for accounting purposes and reported in the executive compensation tables required by the federal securities laws, even though the recipient of the awards may never realize any value from their awards.
31
2025 Summary Compensation Table
The following table provides information regarding the total compensation awarded to, earned by, or paid to our named executive officers for services rendered to us in all capacities for the fiscal years ended December 31, 2023, 2024, and 2025.
| Name and Principal Position | Year | Salary ($)(1) | Bonus ($)(1)(2) | Option Awards ($)(3) | All Other Compensation ($)(4) | Total ($) | ||||||||||||||||||||||||||||||||
| Carl L.G. Hansen, Ph.D. | 2025 | 550,000 | 357,908 | 5,361,934 | 23,244 | 6,293,085 | ||||||||||||||||||||||||||||||||
| Chief Executive Officer | 2024 | 460,000 | 263,840 | 7,498,656 | 22,996 | 8,245,492 | ||||||||||||||||||||||||||||||||
| 2023 | 460,000 | 236,577 | — | 18,362 | 714,939 | |||||||||||||||||||||||||||||||||
| Andrew Booth | 2025 | 485,000 | 218,567 | 2,655,434 | 23,244 | 3,382,244 | ||||||||||||||||||||||||||||||||
| Chief Financial Officer | 2024 | 460,000 | 188,680 | 2,756,858 | 23,040 | 3,428,578 | ||||||||||||||||||||||||||||||||
| 2023 | 460,000 | 191,747 | — | 22,808 | 674,555 | |||||||||||||||||||||||||||||||||
| Véronique Lecault, Ph.D. | 2025 | 454,000 | 204,402 | 1,634,113 | 23,244 | 2,315,758 | ||||||||||||||||||||||||||||||||
| Chief Technology Officer | 2024 | 460,000 | 184,666 | 2,756,858 | 23,040 | 3,424,564 | ||||||||||||||||||||||||||||||||
| 2023 | 460,000 | 167,779 | — | 22,808 | 650,587 | |||||||||||||||||||||||||||||||||
| Tryn Stimart | 2025 | 470,000 | 211,125 | 1,634,113 | 28,150 | 2,343,388 | ||||||||||||||||||||||||||||||||
| Chief Legal Officer, Chief Compliance Officer, Corporate Secretary, and Privacy Officer | 2024 | 460,000 | 194,580 | 2,205,487 | 30,500 | 2,890,567 | ||||||||||||||||||||||||||||||||
| 2023 | 460,000 | 180,090 | — | 27,600 | 667,690 | |||||||||||||||||||||||||||||||||
__________________________
(1)Base salary for all executives is determined in USD. For Canadian resident executives, base salary and bonus is paid in Canadian dollars. The 2025 base salary and bonus amounts are translated here into USD using the 2025 weighted-average exchange ratio of CAD $1.40:USD $1.00 as set forth by the Bank of Canada. The decrease in salary disclosed for Dr. Lecault’s salary is due to foreign exchange conversion.
(2)The amounts reported represent annual discretionary cash incentive bonuses earned by our NEOs, based on our achievement of certain corporate performance and, for our NEOs other than our CEO, individual performance goals for 2025. For more information on these bonuses, see the description of the annual performance bonuses under “Annual Cash Incentive Bonus” above. Dr. Lecault’s 2023 bonus payment was awarded based on 2023 performance, but she declined to accept the bonus.
(3)The amounts reported represent the aggregate grant date fair value of the stock options granted to our named executive officers during the 2024 and 2025 fiscal years, calculated in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 718. Such grant date fair values do not take into account any estimated forfeitures. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 10 of our Consolidated Financial Statements included in our annual report on Form 10-K for the year ended December 31, 2025. The amounts reported in this column reflect the accounting cost for these stock options and do not correspond to the actual economic value that may be received by our named executive officers upon the exercise of the stock options or any sale of the underlying common shares. To better align with the Company’s performance year and company-wide award granting process, the annual NEO equity grant timing was moved from December annually to January, with the first grant occurring in January 2024. As such, no equity awards were granted in 2023.
(4)The amounts reported represent employer contributions to the Canadian NEO’s (Dr. Hansen, Mr. Booth, and Dr. Lecault) RRSP plans and to the American NEO’s (Mr. Stimart) 401 (k) plan. The Canadian RRSP contributions are paid semi-monthly in CAD, and translated here at the 2025 weighted-average exchange ratio of CAD $1.40:USD $1.00 as set forth by the Bank of Canada.
Base Salaries
Amounts represent the actual amount of base salary paid to each NEO during the applicable year. Annual base salary is determined in USD, paid to our Canadian NEO’s in Canadian dollars, and annual salary is effective February 1, 2025.
Annual Bonuses
During the fiscal year ended December 31, 2025, our named executive officers were eligible to earn a discretionary annual bonus based on the achievement of certain Company performance objectives and/or individual performance. For the fiscal year ended December 31, 2025, the target annual bonuses for Dr. Hansen, Mr. Stimart, Dr. Lecault, and Mr. Booth were 65%, 45%, 45%, and 45%, respectively, of the applicable named executive officer’s annual base salary.
32
Equity Compensation
During the fiscal year ended December 31, 2025, we granted stock option awards to each of our named executive officers, as described in more detail in the “Outstanding Equity Awards at Fiscal 2025 Year-End” table.
Perquisites or Personal Benefits
We generally do not provide significant perquisites or personal benefits to our employees with an aggregate value of $10,000 or more, other than relocation expense reimbursement.
2025 Grants of Plan-Based Awards Table
The following table shows information on plan-based awards granted to our NEOs during the fiscal year ended December 31, 2025.
Name(1) | Grant Date | All other Option Awards: Number of Securities Underlying Options (#) | Exercise or Base Price of Option Awards ($) | Grant date fair value of Stock and Option Awards($)(2) | ||||||||||||||||||||||
| Carl L.G. Hansen, Ph.D. | ||||||||||||||||||||||||||
| Annual Stock Option Grant | 1/1/2025 | 2,730,109 | $ | 2.93 | 5,361,934 | |||||||||||||||||||||
| Andrew Booth | ||||||||||||||||||||||||||
| Annual Stock Option Grant | 1/1/2025 | 1,352,054 | $ | 2.93 | 2,655,434 | |||||||||||||||||||||
| Véronique Lecault, Ph.D. | ||||||||||||||||||||||||||
| Annual Stock Option Grant | 1/1/2025 | 832,033 | $ | 2.93 | 1,634,113 | |||||||||||||||||||||
| Tryn Stimart | ||||||||||||||||||||||||||
| Annual Stock Option Grant | 1/1/2025 | 832,033 | $ | 2.93 | 1,634,113 | |||||||||||||||||||||
(1)Represents options granted under our 2020 Plan. Each stock option grant is subject to time-based vesting, as described in the footnotes to the “Outstanding Equity Awards at 2025 Year-End Table” below.
(2)The amounts reported represent the aggregate grant date fair value of the stock options granted to our directors during the 2025 fiscal year, calculated in accordance with ASC Topic 718. Such grant date fair values do not consider any estimated forfeitures. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 10 of our Consolidated Financial Statements included in our annual report on Form 10-K for the year ended December 31, 2025. The amounts reported in this column reflect the accounting cost for these stock options and do not correspond to the actual economic value that may be received by our directors upon the exercise of the stock options or any sale of the underlying common shares.
33
Outstanding Equity Awards at 2025 Fiscal Year-End
The following table sets forth information regarding outstanding equity awards held by our named executive officers as of December 31, 2025:
| Options Awards | ||||||||||||||||||||||||||||||||||||||||||||
| Name | Grant Date(1) | Vesting Commencement Date | Number of Securities Underlying Unexercised Options (#) Exercisable | Number of Securities Underlying Unexercised Options (#) Unexercisable | Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) | Option Exercise Price ($)(2) | Option Expiration Date | |||||||||||||||||||||||||||||||||||||
| Carl L.G. Hansen, Ph.D. | 1/1/2025(7) | 1/1/2025 | — | 2,730,109 | — | 2.93 | 1/1/2035 | |||||||||||||||||||||||||||||||||||||
1/14/2024(7) | 1/14/2024 | 1,004,109 | 1,091,423 | — | 5.39 | 1/14/2034 | ||||||||||||||||||||||||||||||||||||||
12/1/2022(7) | 12/1/2022 | 693,801 | 231,268 | — | 13.18 | 12/1/2032 | ||||||||||||||||||||||||||||||||||||||
12/7/2021(3) | 12/7/2021 | 920,312 | — | — | 14.55 | 12/7/2031 | ||||||||||||||||||||||||||||||||||||||
12/10/2020(4) | 12/10/2020 | 496,000 | — | — | 20.00 | 12/10/2030 | ||||||||||||||||||||||||||||||||||||||
10/29/2020(2)(3) | 10/29/2020 | 3,823,310 | — | — | 2.30 | 10/29/2030 | ||||||||||||||||||||||||||||||||||||||
| Andrew Booth | 1/1/2025(7) | 1/1/2025 | — | 1,352,054 | — | 2.93 | 1/1/2035 | |||||||||||||||||||||||||||||||||||||
1/14/2024(7) | 1/14/2024 | 369,157 | 401,259 | — | 5.39 | 1/14/2034 | ||||||||||||||||||||||||||||||||||||||
12/1/2022(7) | 12/1/2022 | 364,245 | 121,416 | — | 13.18 | 12/1/2032 | ||||||||||||||||||||||||||||||||||||||
12/7/2021(3) | 12/7/2021 | 406,020 | — | — | 14.55 | 12/7/2031 | ||||||||||||||||||||||||||||||||||||||
12/10/2020(4) | 12/10/2020 | 228,800 | — | — | 20.00 | 12/10/2030 | ||||||||||||||||||||||||||||||||||||||
3/23/2020(2)(6) | 3/23/2020 | 1,500,000 | — | — | 0.32 | 8/22/2029 | ||||||||||||||||||||||||||||||||||||||
10/30/2019(2)(3) | 8/22/2019 | 2,950,000 | — | — | 0.32 | 8/22/2029 | ||||||||||||||||||||||||||||||||||||||
12/31/2017(2)(5) | 6/15/2016 | 250,000 | — | — | 0.19 | 6/15/2026 | ||||||||||||||||||||||||||||||||||||||
| Véronique Lecault, Ph.D. | 1/1/2025(7) | 1/1/2025 | — | 832,033 | — | 2.93 | 1/1/2035 | |||||||||||||||||||||||||||||||||||||
1/14/2024(7) | 1/14/2024 | 369,157 | 401,259 | — | 5.39 | 1/14/2034 | ||||||||||||||||||||||||||||||||||||||
12/1/2022(7) | 12/1/2022 | 346,901 | 115,634 | — | 13.18 | 12/1/2032 | ||||||||||||||||||||||||||||||||||||||
12/7/2021(3) | 12/7/2021 | 406,020 | — | — | 14.55 | 12/7/2031 | ||||||||||||||||||||||||||||||||||||||
12/10/2020(4) | 12/10/2020 | 190,800 | — | — | 20.00 | 12/10/2030 | ||||||||||||||||||||||||||||||||||||||
10/29/2020(2)(3) | 10/29/2020 | 2,000,000 | — | — | 2.30 | 10/29/2030 | ||||||||||||||||||||||||||||||||||||||
| Tryn Stimart | 1/1/2025(7) | 1/1/2025 | — | 832,033 | — | 2.93 | 1/1/2035 | |||||||||||||||||||||||||||||||||||||
1/14/2024(7) | 1/14/2024 | 295,326 | 321,007 | — | 5.39 | 1/14/2034 | ||||||||||||||||||||||||||||||||||||||
12/1/2022(7) | 12/1/2022 | 260,175 | 86,726 | — | 13.18 | 12/1/2032 | ||||||||||||||||||||||||||||||||||||||
12/7/2021(3) | 12/7/2021 | 270,680 | — | — | 14.55 | 12/7/2031 | ||||||||||||||||||||||||||||||||||||||
12/10/2020(4) | 12/10/2020 | 190,800 | — | — | 20.00 | 12/10/2030 | ||||||||||||||||||||||||||||||||||||||
10/29/2020(2)(3) | 10/29/2020 | 600,000 | — | — | 2.30 | 10/29/2030 | ||||||||||||||||||||||||||||||||||||||
10/30/2019(2)(3) | 8/22/2019 | 1,250,000 | — | — | 0.32 | 8/22/2029 | ||||||||||||||||||||||||||||||||||||||
__________________________
(1)The stock option awards granted on or after AbCellera’s IPO date of December 10, 2020, were granted under our 2020 Plan. The stock option award is subject to certain acceleration provisions as provided under the Severance Plan.
(2)The stock option award was granted under our Pre-IPO Plan (as defined below). The stock option award is subject to certain acceleration provisions as provided under the Severance Plan. Awards granted prior to AbCellera’s IPO date of December 10, 2020, were granted with a per share exercise price denominated in CAD. In 2021, all pre-IPO award exercise prices were converted, for administrative convenience, from CAD to USD using the Bank of Canada's foreign exchange rate as of the award grant date. Differences in the previously reported option exercise price are attributable to the 2021 conversion compared to previously reported amounts translated at a weighted-average exchange rate.
(3)One-fourth of the shares subject to the stock option vests on the one-year anniversary of the vesting commencement date and the remaining vests in equal quarterly installments for the next three (3) years, subject to the NEO’s continuous service relationship with us through each such date. The stock option award is subject to certain acceleration provisions as provided under the Severance Plan.
(4)One-fourth of the shares subject to the stock option vests on December 31, 2021, and the remaining vests in equal quarterly installments for the next three (3) years, subject to the named executive officer’s continuous service relationship with us through each such date. The stock option award is subject to certain acceleration provisions as provided under the Severance Plan.
(5)One-sixth of the shares subject to the stock option vests on the one-year anniversary of the vesting commencement date and the remaining vests in equal annual installments thereafter for the next five (5) years.
(6)These options were performance-based awards contingent on securing Series B financing. These options were granted and fully vested on March 23, 2020, when the Company secured Series B financing.
34
(7)One-fourth of the shares subject to the stock option vests on the one-year anniversary of the vesting commencement date and the remaining vests in equal monthly installments for the next three (3) years, subject to the named executive officer’s continuous service relationship with us through each such date. The stock option award is subject to certain acceleration provisions as provided under the Severance Plan.
35
2025 Option Exercises and Stock Vesting Table
There were no stock options exercised by our NEOs during the year ended December 31, 2025.
Employment Agreements and Severance Plans
Executive Employment Arrangements
We have entered into an offer letter with each of the named executive officers in connection with their employment with us, which set forth the terms and conditions of their employment.
Offer Letters in Place During the Fiscal Year Ended December 31, 2025, for Our Named Executive Officers
Carl L.G. Hansen, Ph.D.
On August 1, 2019, we entered a continuation of employment letter with Dr. Hansen, who currently serves as our Chief Executive Officer. The offer letter, effective as of September 1, 2019, and amended as of March 6, 2020, provides for Dr. Hansen’s initial annual base salary, initial target annual bonus opportunity, and his participation in our employee benefit plans generally. Dr. Hansen’s offer letter also provides for certain payments and benefits in the event of a termination of employment, which were superseded and replaced by the terms in the Executive Severance Plan, or Severance Plan.
Dr. Hansen is subject to a perpetual non-disclosure of confidential information covenant, an assignment of intellectual property covenant and one (1) year non-compete and non-solicitation of clients and employees covenants following his termination from employment.
Véronique Lecault, Ph.D.
On December 20, 2016, we entered an employment agreement with Dr. Lecault, who currently serves as our Chief Technology Officer. The offer letter, effective as of December 16, 2016 and amended as of June 1, 2018, provided for Dr. Lecault’s annual base salary and her ability to participate in our employee benefit plans generally. It was amended on January 1st, 2019, when she started to serve as Chief Operating Officer, to include an initial target annual bonus opportunity. On January 15, 2020, we entered into a continuation of employment agreement with Dr. Lecault, effective February 1st, 2020, that provides for Dr. Lecault’s annual base salary, initial target annual bonus opportunity and her ability to participate in our employee benefit plans generally. The agreement was amended in 2025, when she started to serve as Chief Technology Officer effective February 18, 2025. Dr. Lecault’s continuation of employment agreement provides that if she voluntarily resigns from the Company, she must provide the Company with three months’ prior written notice, which the Company may waive and provide payment of base salary in lieu of such notice. The employment agreement also provides for certain payments and benefits in the event of a termination of employment, which were superseded and replaced by the terms in the Executive Severance Plan, or Severance Plan.
Dr. Lecault is subject to a perpetual non-disclosure of confidential information covenant, an assignment of intellectual property covenant and one (1) year non-compete and non-solicitation of clients and employees covenants following her termination from employment.
Tryn Stimart, Esq.
On July 10, 2019, we entered an offer letter with Mr. Stimart, who currently serves as our Chief Legal Officer, Chief Compliance Officer, Corporate Secretary, and Privacy Officer. The offer letter, effective as of August 22, 2019, provides for Mr. Stimart’s initial annual base salary, initial target annual bonus opportunity, up to $30,000 for relocation expenses (which Mr. Stimart has not incurred), as well as his ability to participate in our employee benefit plans generally. Mr. Stimart’s offer letter also provides for certain payments and benefits in the event of a termination of employment, which has been superseded and replaced by the terms in the Severance Plan.
Mr. Stimart is subject to a perpetual non-disclosure of confidential information covenant, an assignment of intellectual property covenant and one (1) year non-compete and non-solicitation of clients and employees covenants following his termination from employment.
Andrew Booth
On April 12, 2019, we entered an offer letter with Mr. Booth, who currently serves as our Chief Financial Officer. The offer letter, effective as of August 22, 2019, provides for Mr. Booth’s initial annual base salary, initial target annual bonus
36
opportunity, as well as his ability to participate in our employee benefit plans generally. Mr. Booth’s offer letter also provides for certain payments and benefits in the event of a termination of employment, which has been superseded and replaced by the terms in the Severance Plan.
Mr. Booth is subject to a perpetual non-disclosure of confidential information covenant, an assignment of intellectual property covenant and one (1) year non-compete and non-solicitation of clients and employees covenants following his termination from employment.
Executive Severance Plan
Our Board of Directors adopted the Severance Plan, which became effective on December 10, 2020, and in which our NEOs, and certain other executives, participate. The benefits provided in the Severance Plan replace any severance for which our NEOs may have been eligible under their existing offer letters or other agreements or arrangements.
The Severance Plan provides that upon a (A) termination by us for any reason other than for “cause,” death or “disability,” or (B) resignation for “good reason” as each such term is defined in the Severance Plan, outside of the change in control period (i.e., the period of one year after a “change in control,” as defined in the Severance Plan), an eligible participant will be entitled to receive, subject to the execution and delivery of an effective release of claims in favor of the Company and continued compliance with all applicable restrictive covenants, (i) 18 months of “base salary” (i.e., the higher of the annual base salary in effect immediately prior to the date of termination or the annual base salary in effect for the year immediately prior to the year in which the date of termination occurs) for our Chief Executive Officer and 12 months of base salary for the other named executive officers, and (ii) (x) for U.S. participants, a monthly amount equal to the monthly employer contribution, based on the premiums as of the date of termination, that we would have made to provide health insurance for the U.S. participant if the applicable U.S. participant had remained employed by us for up to 18 months for our Chief Executive Officer (if a U.S. participant) and 12 months for our other named executive officers (if U.S. participants) and (y) for Canadian participants, continued health benefits for 18 months for our Chief Executive Officer (if a Canadian participant) and 12 months for our other named executive officers (if Canadian participants), provided that in no case will a Canadian participant receive less benefit continuation than is required by applicable law. The payments under (i) and (ii) will be paid in substantially equal installments in accordance with our payroll practice over 18 months for our Chief Executive Officer and 12 months for our other named executive officers.
The Severance Plan also provides that upon a (A) termination by us other than for cause, death or disability or (B) resignation for good reason in each case within the change in control period, an eligible participant will be entitled to receive, in lieu of the payments and benefits above and subject to the execution and delivery of an effective release of claims in favor of the Company and continued compliance with all applicable restrictive covenants, (i) a lump sum amount equal to 150% of the base salary and 150% of the target annual bonus in effect immediately prior to the date of termination (or immediately prior to the change in control, if higher) for our Chief Executive Officer and 100% of the base salary and 100% of the target annual bonus in effect immediately prior to the date of termination (or immediately prior to the change in control, if higher) for our other named executive officers, (ii) (x) for U.S. participants, a lump sum amount equal to the monthly employer contribution, based on the premiums as of the date of termination, that we would have made to provide health insurance for the participant if the applicable U.S. participant had remained employed by us for 18 months for our Chief Executive Officer (if a U.S. participant) and 12 months for our other named executive officers (if U.S. participants) and (y) for Canadian participants, continued health benefits for 18 months for our Chief Executive Officer (if a Canadian participant) and 12 months for our other named executive officers (if Canadian participants), provided that in no case will a Canadian participant receive less benefit continuation than is required by applicable law, and (iii) for all outstanding and unvested equity awards of the Company that are subject to time-based vesting held by the participant, full accelerated vesting of such awards; provided, that the performance conditions applicable to any outstanding and unvested equity awards subject to performance-based vesting will be deemed satisfied at the target level specified in the terms of the applicable award agreement.
The payments and benefits provided under the Severance Plan in connection with a change in control may not be eligible for a federal income tax deduction by us pursuant to Section 280G of the Code. These payments and benefits may also subject an eligible participant, including the named executive officers, to an excise tax under Section 4999 of the Code. If the payments or benefits payable in connection with a change in control would be subject to the excise tax imposed under Section 4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net after-tax benefit to the participant.
37
Estimated Payments and Benefits Upon Termination or Change of Control
The amount of compensation and benefits payable to each of our NEOs in various termination of employment and change in control situations, assuming that the triggering event occurred on December 31, 2025, has been estimated in the tables below. The closing price of the Company’s common shares on the NASDAQ Global Select Market as of December 31, 2025, the last trading day of 2025, was $3.42 per share. The value of the unvested stock options was calculated by multiplying the number of unvested options subject to vesting acceleration as of December 31, 2025, by the difference between the closing price of the Company’s common shares as of December 31, 2025, and the exercise price for such unvested option shares.
The following table sets forth the potential payments and benefits upon employment termination or a sale event for our NEOs, as if the triggering event occurred on December 31, 2025:
| Payments and Benefits | Cash Severance Payments ($) | Value of Stock Options ($) | Other Payments ($)(5) | Total ($) | ||||||||||||||||||||||
| Carl L.G. Hansen, Ph.D. | ||||||||||||||||||||||||||
| Termination Not in Connection with a Change in Control | 825,000(1) | — | 8,100 | 833,100 | ||||||||||||||||||||||
| Termination in Connection with a Change in Control | 1,361,250(2) | 1,337,753 | 8,100 | 2,707,103 | ||||||||||||||||||||||
| Andrew Booth | ||||||||||||||||||||||||||
| Termination Not in Connection with a Change in Control | 485,000(3) | — | 5,400 | 490,400 | ||||||||||||||||||||||
| Termination in Connection with a Change in Control | 703,250(4) | 662,506 | 5,400 | 1,371,156 | ||||||||||||||||||||||
| Véronique Lecault, Ph.D. | ||||||||||||||||||||||||||
| Termination Not in Connection with a Change in Control | 454,000(3) | — | 2,445 | 456,445 | ||||||||||||||||||||||
| Termination in Connection with a Change in Control | 658,300(4) | 407,696 | 2,445 | 1,068,441 | ||||||||||||||||||||||
| Tryn Stimart | ||||||||||||||||||||||||||
| Termination Not in Connection with a Change in Control | 470,000(3) | — | 43,383 | 513,383 | ||||||||||||||||||||||
| Termination in Connection with a Change in Control | 681,500(4) | 407,696 | 43,383 | 1,132,579 | ||||||||||||||||||||||
__________________________
(1)Represents eighteen (18) months of base salary.
(2)Represents eighteen (18) months of base salary and 1.5 times the annual target bonus.
(3)Represents twelve (12) months of base salary.
(4)Represents twelve (12) months base salary and annual target bonus.
(5)For Canadian named executive officers (Dr. Hansen, Mr. Booth, and Dr. Lecault) amounts shown in the “Other Payments” column relate to contributions to our extended medical benefits premiums paid in CAD calculated at a ratio of CAD $1.37:USD $1.00 as set forth by the Bank of Canada on December 31, 2025. For the U.S. named executive officer, Mr. Stimart, these amounts relate to monthly COBRA cost of medical insurance elected by Mr. Stimart during the fiscal year 2025, multiplied by twelve (12) months.
38
2025 CEO Pay Ratio
Pursuant to Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(u) of Regulation S-K, we are required to disclose the ratio of the annual total compensation of our principal executive officer to the median of the annual total compensation of all our employees other than our principal executive officer. During fiscal 2025, our principal executive officer was our Chief Executive Officer, Carl L.G. Hansen, Ph.D.
In accordance with Item 402(u) of Regulation S-K, we identified the median employee as of October 31, 2025 (including all employees, whether employed on a full-time or part-time basis), by aggregating for each employee employed on this date, (i) annual base salary or wages for 2025, (ii) target cash incentive compensation for 2025, (iii) company retirement savings contributions and (iv) the estimated accounting value of any equity awards granted during 2025. For employees hired during 2025, we annualized their base salary as if they had been employed for the full year in 2025. We did not exclude workers in non-U.S. countries and, accordingly, compensation paid to employees in a foreign currency were translated to USD using the weighted average foreign exchange rate per the Bank of Canada for the period. We chose this as our consistently applied compensation measure because we believed it was representative of employee compensation at AbCellera. We then ranked our employees from lowest to highest using this compensation measure. This calculation was performed for all our employees who were employed on October 31, 2025, excluding Dr. Hansen. Once we selected the median employee, we calculated this employee’s compensation in the same manner as we calculated Dr. Hansen’s compensation for purposes of the Summary Compensation Table.
For 2025, the annual total compensation for Dr. Hansen, as reported in the Summary Compensation Table, was $6,293,085, and the annual total compensation for our median employee, who is employed as a research scientist, as calculated using Summary Compensation Table requirements was $122,119, resulting in an estimated pay ratio of approximately 52:1.
The pay ratio reported above is a reasonable estimate calculated in a manner consistent with SEC rules based on our internal records and the methodology described above. The SEC rules for identifying the median compensated employee and calculating the pay ratio based on that employee’s annual total compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. Accordingly, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies have different employee populations and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios.
39
2025 Pay Versus Performance Table
As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, we are providing information about the relationship between executive compensation actually paid to our PEO and the other NEOs (as calculated in accordance with Item 402(v) of Regulation S-K) and certain financial performance measures. For additional information on our compensation programs and philosophy and how we design our compensation programs to align pay with performance, see the section titled “Compensation Discussion and Analysis”.
The following table reports the compensation of our CEO (our Principal Executive Officer, or PEO) and the average compensation of the other Named Executive Officers (Non-PEO NEOs) as reported in the Summary Compensation Table in our proxy statements for the past four years, as well as their compensation actually paid, as calculated pursuant to SEC rules and certain performance measures required by the rules. The compensation actually paid values included in the table below reflect a measure of compensation which is a combined realizable and realized pay measure predicated on fair value. The grant date fair values included in the Summary Compensation Table have been replaced with fair values reflecting the change in value of equity awards during the fiscal year. The calculations do not reflect the actual sale of stock underlying equity awards or the exercise of stock options by the executive.
Value of Initial Fixed $100 Investment Based On: | ||||||||||||||||||||||||||||||||||||||||||||
| Year | Summary Compensation Table Total for PEO | Compensation Actually Paid to PEO(1) | Average Summary Compensation Table for Non- PEO NEOs(2) | Average Compensation Actually Paid to Non-PEO NEOs(3) | Total Shareholder Return(4) | Peer Group Total Shareholder Return(5) | Net Income (000's)(6) | |||||||||||||||||||||||||||||||||||||
| 2025 | ( | |||||||||||||||||||||||||||||||||||||||||||
| 2024 | ( | ( | ||||||||||||||||||||||||||||||||||||||||||
| 2023 | ( | ( | ( | |||||||||||||||||||||||||||||||||||||||||
| 2022 | ( | ( | ||||||||||||||||||||||||||||||||||||||||||
| 2021 | ( | ( | ||||||||||||||||||||||||||||||||||||||||||
__________________________
| Year | Summary Compensation Table Total for PEO ($) | Summary Compensation Table Value of Equity Awards ($)(a) | Equity Award Adjustments($)(b) | Compensation Actually Paid to PEO ($) | ||||||||||||||||||||||
| 2025 | ( | |||||||||||||||||||||||||
| 2024 | ( | ( | ( | |||||||||||||||||||||||
| 2023 | ( | ( | ||||||||||||||||||||||||
| 2022 | ( | ( | ( | |||||||||||||||||||||||
| 2021 | ( | ( | ( | |||||||||||||||||||||||
__________________________
(a)The amounts reported represent the sum of the amounts reported in the “Stock Awards” and “Option Awards” columns of the Summary Compensation Table for the applicable fiscal year.
(b)The equity award adjustments for each fiscal year include the following: (i) the addition (or subtraction, if applicable) of the year-end fair value of any equity awards granted in the year that are outstanding and unvested as of the end of the year; (ii) for any awards granted in prior years that are outstanding and unvested as of the end of the fiscal year, the addition (or subtraction, if applicable) of the change in fair value of between the end of the prior fiscal year the end of the applicable fiscal year; and (iii) for awards granted in prior years that vest during the fiscal year, the addition (or subtraction, if applicable) of the change in fair value between the end of the prior fiscal year and the vesting date of
40
such awards. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows:
| Year | Year End Fair Value of Equity Awards ($)(i) | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards ($)(ii) | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year ($)(iii) | Total Equity Award Adjustments ($) | ||||||||||||||||||||||
| 2025 | ||||||||||||||||||||||||||
| 2024 | ( | ( | ( | |||||||||||||||||||||||
| 2023 | ( | ( | ( | |||||||||||||||||||||||
| 2022 | ( | ( | ( | |||||||||||||||||||||||
| 2021 | ( | ( | ( | |||||||||||||||||||||||
(2)The amounts reported represent the average of the amounts reported for the Company’s named executive officers as a group (excluding our PEO), in the “Total” column of the Summary Compensation Table in each applicable year. The names of each of the named executive officers included for purposes of calculating the average amounts were (i) for 2025, 2024, and 2023, Véronique Lecault, Tryn Stimart, and Andrew Booth (ii) for 2022, Véronique Lecault, Tryn Stimart, Andrew Booth, and Neil Aubuchon, and (iii) for 2021, Véronique Lecault, Tryn Stimart, Andrew Booth, and Neil Berkley.
(3)The amounts reported represent the average “compensation actually paid” to the NEOs other than our PEO as a group, computed in accordance with Item 402(v) of Regulation S-K. The amounts do not reflect the actual average amount of compensation earned by or paid to such NEOs as a group in the applicable year. In accordance with Item 402(v) of Regulation S-K, the following adjustments were made were made to the average of the amounts reported in the “Total” column of the Summary Compensation Table for the NEOs as a group (excluding our PEO) for each year to determine the compensation actually paid, using the same methodology described above in footnote 1:
| Year | Average Reported Summary Compensation Table Total for Non-PEO NEOs ($) | Average Summary Compensation Table Value of Equity Awards ($)(a) | Average Equity Award Adjustments ($)(b) | Average Compensation Actually Paid to Non-PEO NEOs ($) | ||||||||||||||||||||||
| 2025 | ( | |||||||||||||||||||||||||
| 2024 | ( | ( | ||||||||||||||||||||||||
| 2023 | ( | ( | ||||||||||||||||||||||||
| 2022 | ( | ( | ( | |||||||||||||||||||||||
| 2021 | ( | ( | ( | |||||||||||||||||||||||
__________________________
(a)The amounts reported represent the average of the sum of the amounts reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable fiscal year.
(b)The equity award adjustments for each fiscal year include the amounts noted in footnote 1(b). The amounts deducted or added in calculating the equity award adjustments are as follows:
| Year | Year End Fair Value of Equity Awards ($) | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards ($) | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year ($) | Total Equity Award Adjustments ($) | ||||||||||||||||||||||
| 2025 | ( | |||||||||||||||||||||||||
| 2024 | ( | ( | ( | |||||||||||||||||||||||
| 2023 | ( | ( | ( | |||||||||||||||||||||||
| 2022 | ( | ( | ( | |||||||||||||||||||||||
| 2021 | ( | ( | ( | |||||||||||||||||||||||
(4)Total shareholder return (“TSR”) is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the Company’s share price at the end and the beginning of the measurement period by the Company’s share price at the beginning of the measurement period.
(5)Represents the weighted peer group TSR. The peer group used for this purpose is the Nasdaq Biotechnology Index (“NBI”), a published industry index.
(6)The dollar amounts reported represent the amount of net income reflected in the Company’s audited financial statements for the applicable fiscal year.
The Company aims to bring antibody drug candidates from target to clinic by combining expertise, technologies, and infrastructure for antibody drug discovery and development. To execute, the Company will continue to invest in its discovery and development capabilities and in its internal pipeline of programs. Future revenues may take time to realize, if
41
at all, and the Company could experience significant fluctuations and unpredictability in annual operating results for the foreseeable future. Further, following the Company’s IPO in December 2020, the Company has experienced significant volatility in its share price. As such, the Company does not consider net income or total shareholder return in setting Company goals and determining executive compensation. Rather, the Company focuses on growth through setting annual goals, as described above in the section titled “Compensation Discussion and Analysis”, that more accurately reflect the discovery and development process, market acceptance, and future economic potential of the Company’s discovery and development capabilities.
Description of the Relationship Between Compensation Actually Paid and Selected Performance Metrics
As described above in the section titled “Compensation Discussion and Analysis”, the Company’s compensation program is designed to attract and retain high-performing talent in our industry, motivate our executive officers to create long-term, enhanced shareholder value, and provide a fair reward for executive effort and stimulate professional and personal growth. The Company uses several performance measures to align executive compensation with Company performance, not all of which are presented in the Pay versus Performance table above. Moreover, the Company calculates compensation to the PEO and other NEOs on a basis different than the amount reported in the Summary Compensation Table and compensation actually paid, as calculated in accordance with Item 402(v) of Regulation S-K, is not considered by the Board and the Compensation Committee in evaluating or determining executive compensation. In accordance with Item 402(v) of Regulation S-K, the Company is providing the following descriptions of the relationships between compensation actually paid and the financial performance metrics presented in the Pay versus Performance table.
Compensation Actually Paid and Company TSR
The graph below shows the relationship between the compensation actually paid to our PEO and the average compensation actually paid to the Company’s other NEOs and the Company’s TSR for the five years presented in the Pay versus Performance table. The Company does not use TSR as a performance measure in its executive compensation program.
Compensation Actually Paid and Net Income
The graph below shows the relationship between compensation actually paid to our PEO and the average compensation actually paid to the Company’s other NEOs to the Company’s net income for the five years presented in the Pay versus Performance table. The Company does not use net income as a performance measure in its executive compensation program.
42
43
Equity Compensation Plan Information
The following table provides information as of December 31, 2025, regarding our common shares that may be issued under our equity compensation plans, consisting of our 2020 Share Option and Incentive Plan, or 2020 Plan, our Seventh Amended and Restated Stock Option Plan, or Pre-IPO Plan, and our 2020 Employee Stock Purchase Plan, or our ESPP.
| Plan Category | Number of Shares of Common Stock to be Issued Upon Exercise of Outstanding Options (#)(2) | Weighted-Average Exercise Price of Outstanding Options ($)(3) | Number of Shares of Common Stock Remaining Available for Future Issuance Under Equity Compensation Plans (#) (Excluding Securities Reflected in The First Column) | |||||||||||||||||
Equity compensation plans approved by security holders(1) | 69,302,644 | 4.87 | 31,911,780 | |||||||||||||||||
| Equity compensation plans not approved by security holders | — | — | — | |||||||||||||||||
| Total | 69,302,644 | 4.87 | 31,911,780 | |||||||||||||||||
__________________________
(1)As of March 31, 2026, there were 33,758,986 shares available for grant under the 2020 Plan, no shares available for grant under the Company’s 7th Amended Pre-IPO Plan, and 1,119,160 shares available for grant under the ESPP.
(2)Includes RSUs.
(3)Does not include RSUs, which do not have an exercise price.
Compensation Committee Interlocks and Insider Participation
None of the members of our compensation committee is or has at any time during the prior three years been, one of our officers or employees. None of our executive officers currently serve, or have in the past fiscal year served, as a member of the Board of Directors or compensation committee of any entity that has one or more of its executive officers serving as a member of our Board of Directors or our compensation committee.
Compensation Committee Report
The compensation committee has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K with our management. Based on this review and discussion, the compensation committee recommended to our Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement.
This report of the compensation committee is not “soliciting material,” shall not be deemed “filed” with the SEC and shall not be incorporated by reference by any general statement incorporating by reference this proxy statement into any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent that we specifically incorporate this information by reference, and shall not otherwise be deemed filed under such acts.
| THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF ABCELLERA BIOLOGICS INC. | |||||
Dr. Michael Hayden, Chair, Mr. John S. Montalbano | |||||
44
CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS
The following is a description of transactions or series of transactions since January 1, 2025, to which we were or will be a party, in which:
•the amount involved in the transaction exceeds, or will exceed $120,000; and
•in which any of our executive officers, directors or holders of 5% or more of any class of our share capital, or the immediate family members of, or any person sharing the household with, the foregoing persons, or any affiliated entities, had or will have a direct or indirect material interest.
There were no related party transactions during the year ended December 31, 2025. Compensation arrangements for our named executive officers and our directors are described elsewhere in this proxy statement under the sections titled “Executive Compensation” and “Director Compensation.”
Executive Officers and Directors Compensation
See the sections titled “Executive Compensation” and “Director Compensation” appearing elsewhere in this proxy statement for information regarding compensation arrangements and share option grants for our executive officers and our directors.
Indemnification Agreements
We have entered into indemnification agreements with our directors and executive officers. These agreements will, among other things, require us to indemnify these individuals for certain expenses (including attorneys’ fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person’s status as a member of our Board of Directors to the maximum extent allowed under Canadian law.
Policies for Approval of Related Party Transactions
Our Board of Directors reviews and approves transactions with directors, officers and holders of five percent or more of our voting securities and their affiliates, each a related party. We have adopted a written related party transactions policy that will require such transactions must be submitted to the Chief Legal Officer and approved by our Audit Committee. Pursuant to this policy, the Audit Committee has the primary responsibility for reviewing and approving or disapproving “related party transactions,” which are transactions between related persons and us in which the aggregate amount involved exceeds or may be expected to exceed $120,000, and in which a related person has or will have a direct or indirect material interest. For purposes of this policy, a related person will be defined as a director, executive officer, nominee for director, or greater than 5% beneficial owner of our common shares, in each case since the beginning of the most recently completed year, and their immediate family members.
45
PRINCIPAL SHAREHOLDERS
The following table presents information concerning the beneficial ownership of our common shares as of April 1, 2026, by:
•each person we know to be the beneficial owner of 5% or more of our outstanding share capital;
•each of our directors and director nominees;
•each of our named executive officers; and
•all of our current executive officers and directors as a group.
We have determined beneficial ownership in accordance with SEC rules. The information does not necessarily indicate beneficial ownership for any other purpose. Under these rules, a person is deemed to be a beneficial owner of our common shares if that person has a right to acquire ownership within sixty (60) days by the exercise of options. A person is also deemed to be a beneficial owner of our common shares if that person has or shares voting power, which includes the power to vote or direct the voting of our common shares, or investment power, which includes the power to dispose of or to direct the disposition of such share capital. Except in cases where community property laws apply or as indicated in the footnotes to this table, we believe that each shareholder identified in the table possesses sole voting and investment power over all common shares shown as beneficially owned by the shareholder.
Percentage of beneficial ownership in the table below is based on 303,946,508 common shares outstanding as of April 1, 2026. Common shares subject to options that are currently exercisable or exercisable within sixty (60) days of April 1, 2026, are considered outstanding and beneficially owned by the person holding the options for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated below, the address of each individual listed below is c/o AbCellera Biologics Inc., 150 W 4th Avenue, Vancouver, BC V5Y 1G6.
| Name and address of beneficial owner | Number of shares beneficially owned (#) | Percentage of shares beneficially owned | ||||||||||||
| 5% or Greater Shareholders: | ||||||||||||||
Thermopylae Holdings Ltd.(1) | 56,134,097 | 18.5 | % | |||||||||||
Baker Bros. Advisors LP(2) | 27,525,640 | 9.1 | % | |||||||||||
| Named Executive Officers and Directors: | ||||||||||||||
Carl L.G. Hansen, Ph.D.(3) | 65,194,311 | 20.9 | % | |||||||||||
Tryn Stimart(4) | 3,245,162 | * | ||||||||||||
Véronique Lecault, Ph.D.(5) | 13,332,328 | 4.3 | % | |||||||||||
Andrew Booth(6) | 6,976,307 | 2.2 | % | |||||||||||
Michael Hayden, MBCHB (M.D.), Ph.D.(7) | 2,102,621 | * | ||||||||||||
John S. Montalbano CFA(8) | 1,016,979 | * | ||||||||||||
Stephen R. Quake, D.Phil.(9) | 1,100,436 | * | ||||||||||||
All directors and executive officers as a group (7 persons)(10) | 92,968,144 | 28.4 | % | |||||||||||
__________________________
*Represents beneficial ownership of less than one percent.
(1)Consists of 56,134,097 common shares held by Thermopylae Holdings Ltd. or Thermopylae, which is an entity wholly owned by Dr. Hansen.
(2)Based solely on the Schedule 13G/A filed with the SEC on November 14, 2024, by Baker Bros. Advisors LP. Consists of 27,525,640 common shares held by Baker Bros. Advisors LP and/or one or more of its investment adviser subsidiaries, which may include Baker Brothers Life Sciences, L.P. and 667, L.P. The principal business address of Baker Bros. Advisors LP is 860 Washington Street, 3rd Floor, New York, NY 10014.
(3)Consists of (i) the common shares listed in footnote (1) and (ii) 898,000 common shares held by Dr. Hansen, and (iii) 8,162,214 common shares underlying options exercisable within 60 days of April 1, 2026.
(4)Consists of (i) 250 common shares held by Mr. Stimart, (ii) 250 shares held by Mr. Stimart’s spouse, and (iii) 3,244,662 common shares underlying options exercisable within 60 days of April 1, 2026.
(5)Consists of (i) 7,155,008 common shares held by Pacific Swell Capital Corp., or Pacific Swell, (ii) 273,630 common shares held by Slomo Family Trust (2019), of which Dr. Lecault is a trustee, (iii) 61,580 common shares held by the spouse of Dr. Lecault, (iv) 2,123,456 common shares held by Dr. Lecault, and (v) 3,718,654 common shares underlying options exercisable within 60 days of April 1, 2026. Dr. Lecault is a director of Pacific Swell and shares voting and dispositive power with respect to the shares held by Pacific Swell. The principal business address of Pacific Swell is 100 – 1312 Lonsdale Avenue, North Vancouver, BC, Canada V7M2H8.
46
(6)Consists of (i) 195,600 common shares held by Mr. Booth, (ii) 130,959 common shares held by Mr. Booth’s spouse, and (iii) 6,649,748 common shares underlying options exercisable within 60 days of April 1, 2026.
(7)Consists of (i) 1,323,397 common shares held by Genworks 2 Consulting, Inc., or Genworks 2, (ii) 118,245 shares held by Dr. Hayden’s spouse, and (iii) 660,979 common shares underlying options exercisable within 60 days of April 1, 2026. Dr. Hayden’s spouse has sole voting and investment power with respect to the shares held by Genworks 2. The principal business address of Genworks 2 is 4484 West 7th Avenue, Vancouver, BC, Canada V6R1W9.
(8)Consists of (i) 221,000 common shares held by Mr. Montalbano, (ii) 5,000 common shares held by Mr. Montalbano’s spouse, and (iii) 790,979 common shares underlying options exercisable within 60 days of April 1, 2026.
(9)Consists of (i) 371,056 common shares held by Dr. Quake, (ii) 264,300 common shares held by a family foundation of which Dr. Quake is a director, and (iii) 465,080 common shares held in a trust for the benefit of Dr. Quake's children of which Dr. Quake is a trustee.
(10)Consists of (i) 69,740,908 common shares held directly or indirectly and (ii) 23,227,236 common shares issuable upon exercise of options exercisable within 60 days of April 1, 2026.
DELINQUENT SECTION 16(A) REPORTS
Section 16(a) of the Exchange Act requires the company’s officers, as defined by Section 16, directors, and persons or entities who own more than 10% of a registered class of the company’s equity securities, to file initial reports of ownership and reports of changes in ownership with the SEC. Such persons or entities are required by SEC regulations to furnish the company with copies of all Section 16(a) forms they file. To our knowledge, based solely on our review of the copies of such filings and based on written representations from reporting persons, we believe that all such reporting persons and entities complied on a timely basis with all Section 16(a) of the Exchange Act filing requirements during the fiscal year ended December 31, 2025, except with respect to the following:
•On July 1, 2025, a Form 4 was filed for Michael Hayden, MBCHB, (M.D.) Ph.D. to report the annual director equity grant aligned the Company's Non-Employee Director Compensation Policy that occurred on June 12, 2025. The delay in filing was due to an administrative issue related to the EDGAR Next transition.
•Stephen R. Quake, D.Phil., was appointed as a director on November 6, 2025. On December 19, 2025, a Form 3 and a Form 4 was filed for his initial beneficial ownership and new director equity grant aligned the Company's Non-Employee Director Compensation Policy, respectively. The filing delay was due to processing his Form IDs during the EDGAR Next transition.
47
REPORT OF THE AUDIT COMMITTEE
The Audit Committee is appointed by the Board of Directors to assist the Board of Directors in fulfilling its oversight responsibilities with respect to (1) the integrity of our consolidated financial statements and financial reporting process and systems of internal controls regarding finance, accounting, and compliance with legal and regulatory requirements, (2) the qualifications, independence, and performance of our independent registered public accounting firm, (3) the performance of our internal audit function, if any, and (4) other matters as set forth in the charter of the Audit Committee approved by the Board of Directors.
Management is responsible for the preparation of our consolidated financial statements and the financial reporting process, including its system of internal control over financial reporting and its disclosure controls and procedures. The independent registered public accounting firm is responsible for performing an audit of our consolidated financial statements in accordance with the standards of the Public Company Accounting Oversight Board (PCAOB) and issuing a report thereon. The Audit Committee’s responsibility is to monitor and oversee these processes.
In connection with these responsibilities, the Audit Committee reviewed and discussed with management and the independent registered public accounting firm our audited consolidated financial statements for the fiscal year ended December 31, 2025. The Audit Committee also discussed with the independent registered public accounting firm the matters required to be discussed under the PCAOB and SEC requirements. In addition, the Audit Committee received written communications from the independent registered public accounting firm confirming their independence as required by the applicable requirements of the PCAOB and has discussed with the independent registered public accounting firm their independence.
Based on the reviews and discussions referred to above, the Audit Committee recommended to the Board of Directors that the audited consolidated financial statements of our company be included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, that was filed with the SEC. The information contained in this report shall not be deemed to be (1) “soliciting material,” (2) “filed” with the SEC, (3) subject to Regulations 14A or 14C of the Exchange Act, or (4) subject to the liabilities of Section 18 of the Exchange Act. This report shall not be deemed incorporated by reference into any of our other filings under the Exchange Act or the Securities Act, except to the extent that we specifically incorporate it by reference into such filing.
THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ABCELLERA BIOLOGICS INC. | |||||
| John S. Montalbano, CFA, Chair | |||||
Stephen R. Quake, D.Phil. | |||||
| Michael Hayden, MBCHB, (M.D.) Ph.D. | |||||
April 29, 2026 | |||||
48
HOUSEHOLDING
Some banks, brokers and other nominee record holders may be participating in the practice of “householding” proxy statements and annual reports. This means that only one copy of our documents, including the annual report to shareholders and proxy statement, may have been sent to multiple shareholders in your household. We will promptly deliver a separate copy of either document to you upon written or oral request to AbCellera Biologics Inc., 150 W 4th Avenue, Vancouver, BC V5Y 1G6, Attention: Corporate Secretary, telephone: (604) 559-9005. If you want to receive separate copies of the proxy statement or annual report to shareholders in the future, or if you are receiving multiple copies and would like to receive only one copy per household, you should contact your bank, broker or other nominee record holder, or you may contact us at the above address and phone number.
SHAREHOLDER PROPOSALS
A shareholder who would like to have a proposal considered for inclusion in our 2027 proxy statement must submit the proposal in accordance with the procedures outlined in Rule 14a-8 of the Exchange Act so that it is received by us no later than December 31, 2026. However, if the date of the 2027 Annual Meeting of Shareholders is changed by more than 30 days from the date of the previous year’s meeting, then the deadline is a reasonable time before we begin to print and send our proxy statement for the 2027 Annual Meeting of Shareholders. SEC rules set standards for eligibility and specify the types of shareholder proposals that may be excluded from a proxy statement. Shareholder proposals should be addressed to AbCellera Biologics Inc., 150 W 4th Avenue, Vancouver, BC V5Y 1G6, Attention: Corporate Secretary.
The BCBCA also sets out the requirements for a valid proposal and provides for the rights and obligations of our company and the submitter upon a valid proposal being made. Proposals submitted under the applicable provisions of the BCBCA that a shareholder intends to present at next year’s Annual Meeting and wishes to be considered for inclusion in our proxy statement and form of proxy relating to next year’s Annual Meeting must be received at least three months before the anniversary of our last annual general meeting. Such proposals must also comply with all applicable provisions of the BCBCA and the regulations thereunder.
If a shareholder wishes to propose a nomination of persons for election to our Board of Directors or present a proposal at an Annual Meeting but does not wish to have the proposal considered for inclusion in our proxy statement and proxy card, our articles establish an advance notice procedure for such nominations and proposals. See “Corporate Governance—Director Nomination Process.”
OTHER MATTERS
Our Board of Directors does not know of any other matters to be brought before the Annual Meeting. If any other matters not mentioned in this proxy statement are properly brought before the meeting, the individuals named in the enclosed proxy intend to use their discretionary voting authority under the proxy to vote the proxy in accordance with their best judgment on those matters.
49